前往化源商城

80-07-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:mu-type opioid receptor isoform MOR-1 [Homo sapiens]
External ID: OPRM1-OPRD1_AG_LUMI_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that activate heterodimer formation between the mu (OPRM1) and delta (OPRD1) opioid receptors, resulting in membrane recruitment of beta-arrestin. The assay monitors GPCR-beta-arrestin proximity using low affinity fragment complementation of beta-galactosidase (beta-gal). This assay employs U2OS cells which express OPRD1, OPRM1 fused to a beta-gal peptide fragment (enzyme donor), and beta-arrestin fused to the complementary beta-gal fragment (enzyme acceptor). Cells are incubated with test compound, followed by measurement of well luminescence. As designed, compounds that induce formation of OPRD1 homodimers or OPRM1-OPRD1 (Mu-Delta) heterodimers will cause beta-arrestin recruitment, resulting in reconstitution of the beta-gal holoenzyme. The reconstituted holoenzyme can then catalyze the hydrolysis of a substrate which yields a chemiluminescent signal, resulting in increased well luminescence. Deltorphin B will be used as the high (100% RLU) control for agonists, and wells containing cells treated with DMSO will be used as the low (0% RLU) control. Compounds were tested in singlicate at a final nominal concentration of 9.3 uM.

Protocol Summary:

The U2OS-OPRM1-OPRD1 (Mu-Delta) cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of a 1:1 mixture of Ham's F-12 Nutrient Media (F-12) and Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% v/v heat-inactivated certified fetal bovine serum, 25 mM HEPES, 250 ug/mL Geneticin, 250 ug/mL Hygromycin B, 0.25 ug/mL Puromycin and 1X antibiotic mix (penicillin, streptomycin, and neomycin).

The day before the assay 1000 cells in 3 uL of cell plating media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 23 hours. Next, 28 nL of test compound in DMSO, Deltorphin B (0.9 uM final concentration) in DMSO, or DMSO alone were dispensed to the appropriate wells. The plates were then incubated for 3 hours at 37 C, 5% CO2, and 95 % RH. The assay was started by adding 2 uL of PathHuntertrade mark reagent (prepared according to the manufacturer's protocol); followed by 1 hour incubation at room temperature. Then, Well Luminescence was read on the ViewLux plate reader

The percent activation for each compound was calculated as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

High_Control is defined as wells containing cells, Deltorphin B and DMSO.
Test_Compound is defined as wells containing cells, test compounds and DMSO.
Low_Control is defined as wells containing cells and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated: (1) the average percent activation of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % activation than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-2, and for inactive compounds 2-0.

List of Reagents:

PathHuntertrade mark B-arrestin recruitment assay, containing the U2OS OPRM1 OPRD1 Beta-arrestin cell line; PathHunter Detection Kit (DiscoveRx, part, 93-0558C3)
Ham's F-12 media (Invitrogen, part 11765-054)
DMEM media (Invitrogen, part 11995-073)
Detachin (Genlantis, part T100100)
Heat Inactivated Fetal Bovine Serum (Invitrogen, part 10082-147)
Puromycin (Invitrogen, part A11138-02)
Hygromycin B (Invitrogen, part 10687-010)
Geneticin (Invitrogen, part 10131-027)
100X Penicillin-Streptomycin-Neomycin mix (Invitrogen, part 15640-055)
T-175 tissue culture flasks (Nunc, part 159910)
Agonist: Deltorphin B (Anaspec, part 62683)
1536-well plates (Greiner, part 789173)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 9.3 uM
4.41
4.41
4.41
4.41
4.41
4.41
4.41
4.41
4.41
4.41
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:RecName: Full=Sialate O-acetylesterase; AltName: Full=H-Lse; AltName: Full=Sialic acid-specific 9-O-acetylesterase; Flags: Precursor [Homo sapiens]
External ID: SIAE_INH_FP_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this biochemical assay is to identify compounds that act as inhibitors of sialic acid acetylesterase (SIAE). In this assay, SIAE protein is incubated with test compounds and fluorophosphonate-rhodamine (FP-Rh) activity-based probe. The reaction is excited with linear polarized light and the intensity of the emitted light is measured as the polarization value (mP). As designed, test compounds that act as SIAE inhibitors will prevent SIAE-probe interactions, thereby increasing the proportion of free (unbound) fluorescent probe in the well, leading to low fluorescence polarization. Compounds are tested in singlicate at a nominal test concentration of 9.66 micromolar.

Protocol Summary:

Prior to the start of the assay, 3 microliters of assay buffer (1X DPBS and 0.01% Pluronic F-127) were dispensed into column 1 thru column 3 of 1536 microtiter plates. Next, 3 microliters of assay buffer containing 0.73uM of SIAE protein were dispensed into columns 4 thru 48. Then, 39 nL of test compound in DMSO or DMSO alone (0.97% final concentration) were added to the appropriate wells and incubated for 45 minutes at 25 degrees Celsius.

The assay was started by dispensing 1.0 microliter of 300 nM FP-Rh in assay buffer to all wells. Plates were centrifuged and after 120 minutes of incubation at 25 degrees Celsius, fluorescence polarization was read on a Viewlux microplate reader (PerkinElmer, Turku, Finland) using a BODIPY TMR FP filter set and a BODIPY dichroic mirror (excitation = 525nm, emission = 598nm) for 25 seconds for each polarization plane (parallel and perpendicular).

Prior to further calculations, the following formula was used to calculate fluorescence polarization (FP):

FP = ( Raw1 - Raw2 ) / ( Raw1 + Raw2 )

Where:

Raw1 is defined as the S channel.
Raw2 is defined as the P channel.

The percent inhibition for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells containing SIAE protein in the presence of test compound and FP-Rh.
High_Control is defined as wells containing DMSO, FP-Rh but, no SIAE protein.
Low_Control is defined as the median of the wells containing test compounds.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-2, for inactive 2-0.

List of Reagents:

SIAE protein (supplied by Assay Provider)
FP-Rh probe (supplied by Assay Provider)
DPBS (Mediatech, part 20-031-CV)
Pluronic F-127 (Invitrogen, part P6866)
1536-well plates (Greiner, part 789176)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 9.66 uM
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53600
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043054 uM-Replicate_1Activity at 0.0000099513 uM-Replicate_1Activity at 0.0000394398 uM-Replicate_1Activity at 0.0000922287 uM-Replicate_1Activity at 0.0002147056 uM-Replicate_1Activity at 0.0004452702 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00376 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000411.68960.1156-13.79419.96613.16310.7283-0.13048.42250.8152-0.10070.800321.2177-5.098911.6896QC'd by GVKInconclusive22.349231.210810Partial curve; partial efficacy; poor fit-4.65074.95490.8311
Inactive00044.1278-1.2132-0.531.1724-13.6008-15.8488-1.6086-19.5261-1.84034.6782.76125.28040.28044.1278QC'd by SequoiaInactive0
Inactive0004-9.80083.31944.9321-4.8812-12.78760.30429.0414-8.94990.223314.08858.8057-15.4411-4.9694-9.8008QC'd by TocrisInactive0
Inactive0004-1.97565.0865-1.7855-7.44442.244-1.822215.634118.165121.11031.735-10.98693.971310.803-1.9756QC'd by MicrosourceInactive0
Inactive00046.85951.21214.5834-1.147427.33062.48186.32539.01910.214520.70491.9499-9.1091-8.70446.8595QC'd by SIGMAInactive0
Inactive0-4.80072.09370.639333.4297-12.96840 0 0 0 0 0 0 0 0 0 0 1 0 0 025.4284-14.8066-9.0853-13.581-7.588-35.7992-8.9477-21.4634-0.5226-3.92488.5216-5.58437.506325.4284QC'd by MicrosourceInactive0
Inactive0004-15.007-3.1282-9.3591-0.59167.66516.92395.64735.12210.15582.5991-1.3526-6.47-0.785-15.007QC'd by MicrosourceInactive0
Inactive000424.0896-0.8446-9.61-6.08550.45112.491311.00488.98224.16252.593115.94870.8545-5.437324.0896QC'd by VitasInactive0
Inactive0004-17.67891.269819.24249.9274-7.42686.6741.6608-11.9547-6.5433-0.12947.7321-0.9298-3.0587-17.6789QC'd by SequoiaInactive0
Inactive0004-14.1816-14.82752.70742.3606-2.2355-4.2683-14.785-4.9866-14.55780.587-5.4301-8.78443.5884-14.1816QC'd by MicrosourceInactive0-9.20073.19250.6375
Inactive0004-1.2316-19.54044.6965-1.2942-1.67070.2407-15.5972-0.1313-8.4723-7.3738-1.20892.41540.8864-1.2316QC'd by SequoiaInactive0
Inactive00041.5567-5.753613.963810.2956-0.5580-1.68249.770620.988-2.01438.1577-7.9909-2.67841.5567QC'd by VitasInactive0
Inactive0-5.00071.96730.395926.0362-2.459340 0 0 0 0 0 0 0 0 1 0 0 0 0 10.23290.7504-0.0238-13.01490.91413.2757.6-0.817-14.514333.15894.5704-6.010126.66430.2329QC'd by VitasInactive0-7.85074.95490.3764
Inactive00040.4996-11.00798.4449-5.51661.0437-5.31884.2154-11.5318-0.68280.560410.3541-10.0764-3.39490.4996QC'd by SequoiaInactive0
Inactive0004-11.29821.6112-9.15080.0988-19.993-7.174916.2891-28.8965-0.2185-13.4455-15.182-7.4087.9797-11.2982QC'd by SIGMAInactive0
Cytotoxic0.001329.371420Complete curve; partial efficacy; poor fit-8.90074.95490.6762-1.930827.4406-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 02.084327.380322.2956-1.7991-14.5009-13.0557-1.27961.8292-4.68462.1858-2.80191.152812.67842.0843QC'd by MicrosourceInactive0
Cytotoxic22.349237.143520Single point of activity-4.65074.95490.6826-37.6249-0.4814-30 0 0 0 0 0 1 0 0 0 0 0 0 0 0-35.0886-10.0183-3.78480.92698.32995.971651.8329-7.9197-7.10119.7258-3.0119-1.82540.4137-35.0886QC'd by MicrosourceCytotoxic19.918841.056720Single point of activity-4.70074.50450.7845
Inactive0004-8.20534.878-0.8843.033-7.545116.823-9.3197.52683.3384-2.1505-2.9445-18.3014-0.1048-8.2053QC'd by SpecsInconclusive25.076243.037610Single point of activity-4.60074.95490.5622
Inactive000420.76650.814812.61279.9828-12.22150.44040.7956-15.56271.1625-6.82596.0669-0.0505-1.196720.7665QC'd by Prestwick Chemical; Inc.Inconclusive22.349234.562510Single point of activity-4.65074.0950.9286
Inconclusive8.897437.738210Single point of activity-5.05073.1320.718338.15130.413130 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.95941.40094.89037.6788-4.8095-4.8507-6.912-0.4163-7.58221.59434.88844.768442.6535-5.9594QC'd by MicrosourceInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS958
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043235 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000380988 uM-Replicate_1Activity at 0.0000933477 uM-Replicate_1Activity at 0.0002146311 uM-Replicate_1Activity at 0.0004426192 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00957 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.768 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000415.4129-0.3878-0.18645.37348.8557-0.29272.5035-10.205-0.2227.988-2.2891.52765.497915.4129QC'd by ACCInactive0
Inactive0-9.30074.95490.81131-17.707840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0149-13.08993.2756-1.32141.18321.8535-0.3978-0.4282.5506-0.24571.49181.68870.55861.0149QC'd by ACCInactive0
Inactive00040.0279-7.8342-1.89942.16960.5638-6.7392.6266-0.50970.73195.3764-7.7238-0.06747.02780.0279QC'd by ACCInactive0
Inactive00041.38786.287211.3346-1.35856.9465-2.58585.0519-2.5689.0021.6411-1.72927.00831.07741.3878QC'd by ACCInactive0-5.45072.40640.4602
Inactive0004-6.0549-14.8117-16.0755-3.9155-14.9771-10.937-32.5334-11.9531.4447-12.5843-18.1191-11.5121-10.2319-6.0549QC'd by RTIInactive0
Inactive0004-22.5649-3.3758-16.2168-4.5428-4.51510.1292-2.6754-23.201-8.3262-3.0518-1.1305-3.6383-2.6115-22.5649QC'd by RTIInactive0-8.59910.80.691
Inactive0004-0.2302-3.0733-11.95531.9394-0.062-0.7676-9.0695-1.09531.199-3.6509-10.3544-18.6262-9.6473-0.2302QC'd by RTIInactive0-4.20294.95490.345
Inactive0004-31.97-9.3562-1.8629-4.3936-8.3595-10.443-39.3827-2.50720.54372.3156-5.5145-4.9746-4.5578-31.97QC'd by RTIInactive0
Cytotoxic48.936540.016120Single point of activity-4.31044.95490.9076-41.0161-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 10.8752-0.1555-0.1471-0.86110.5088-1.62211.8567-5.5667-4.26740.6449-1.1659-1.471-37.97790.8752QC'd by RTIInactive0
Inactive0-4.4812.25260.6231-17.4881-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.1568-8.0428-0.62356.2346-0.9991-1.44871.2877-1.82882.3924-2.4336-0.4068-0.0819-10.8685-14.1568QC'd by RTIInactive0
Inactive0-4.15464.95490.3365-27.53820.41540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.24640.0979-1.09382.89261.68642.0417-11.5049-1.00074.87532.0771-10.214919.6036-0.4282-21.2464QC'd by RTIInactive0-4.35463.92950.4572
Cytotoxic1.909462.99420Single point of activity-5.71914.95490.8427-65.284-2.29-30 0 0 0 0 0 0 0 0 0 0 1 1 1 121.2448-4.4527-11.9693-0.7569-1.67770.0603-12.88981.4183.8556-64.004-3.125819.149730.660221.2448QC'd by RTIInconclusive26.970339.101610Partial curve; partial efficacy-4.56912.40640.8048
Inactive0-5.73594.95490.4398-11.70950.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.5079-13.1487-1.13453.01137.6647-1.76074.95091.42740.7821-7.5706-10.5531-11.2568-1.1121-18.5079QC'd by RTIInactive0-5.13593.990.4729
Inactive0-4.91744.95490.4007150.513840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.2124-6.4957-1.34376.24526.8209-1.5109-0.187612.48363.7645-4.0819-5.983812.929113.901-8.2124QC'd by RTIInactive0
Inactive0004-4.309910.7843-0.2327-5.32226.8375-6.64633.82231.011417.173-2.68034.8346-1.5527-1.3315-4.3099QC'd by RTIInactive0
Inactive0-4.78644.95490.4643-0.5-6.943640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.3412-9.0513-3.5748-2.3634-8.2237-8.0106-6.3527-9.1377-10.7863-6.9009-9.556-4.63561.3663-2.3412QC'd by RTIInactive0
Inactive00043.8948-9.18-4.528-7.8262-5.28180.1213-2.8514-5.27810.14171.4481-10.28080.21445.40843.8948QC'd by RTIInactive0-4.27824.0450.5133
Inactive00040.9309-0.3627-0.7959-0.29194.6133-6.45136.07670.37295.22822.4365-0.3736-6.44071.19840.9309QC'd by RTIInactive0
Inactive00044.6175-2.446-2.97794.96498.591-3.7225-1.29327.6265.56985.46650.618212.56510.39614.6175QC'd by RTIInactive0
Inactive00041.16141.11370.8635-2.0253-1.3109-1.0103-7.7297-0.07730.3904-0.9231-0.2649-8.99091.4551.1614QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS482
Protocol: Please refer to other AIDs 1963578, 1963580, 720687, 720685, 720678 and 720681 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with rat microsomes agonist mode assay (AID 1963578), cell viability counter screen (AID 1963580), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0active antagonist37.95478669-56.89862383inactiveRohm and Haas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactivePfaltz-Bauer
inactiveinactive0inactive0inactive0inactive0inactiveRadian International
inactiveinactive0inactive0inactive0inconclusive antagonistinactiveSpectrum Chemical
inactiveinactive0inconclusive agonistinactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveBattelle Northwest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inconclusive agonistinactive0inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist11.47389904-137.559426inactiveTCI
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusiveinactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveShanghai Xingling
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53344
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043054 uM-Replicate_1W530-Activity at 0.0000099513 uM-Replicate_1W530-Activity at 0.0000394398 uM-Replicate_1W530-Activity at 0.0000922287 uM-Replicate_1W530-Activity at 0.0002147056 uM-Replicate_1W530-Activity at 0.0004452702 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00376 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-2.7054-0.742917.6324-5.7098-2.4442-8.8689-8.44923.85664.8951.316-4.2342-2.2173-1.3067-2.705410004-0.008
Inactive10004-9.2163-14.98060.5352-3.1889-1.87493.657-6.40320.83436.099515.97381.8503-6.6623-7.3549-9.2163100040.5551
Inconclusive15.82281.873510Partial curve; high efficacy-4.80071.46410.942883.86851.9952.11 0 0 0 0 0 0 0 0 0 0 0 0 0 063.7671-25.2350.72594.9823.8964-6.011-7.50423.0243-0.36318.58029.552814.338143.879163.767110-5.15071.41630.6697-11.5276040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.41
Inactive10004-7.60360.157-0.8011-9.9636-13.0521-10.3016-8.2965-19.3101-11.1767-1.8658-10.3506-0.2558-4.7484-7.6036100040.7786
Inactive10004-1.25980.187213.2885.11046.52950.1337-12.0409-9.16955.1910.756-5.7729-4.064311.1384-1.2598100040.0274
Inactive10-4.79910.60.5308-18.20022.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.66682.13790.73361.997911.88191.0068-5.4624-1.91134.135-9.1428-3.5388-7.7512-8.3149-12.6668100042.1474
Inactive100040.120.6216.73751.29862.96138.4418-20.9196-8.36372.5119-0.9643-3.05170.98720.45280.12100040.1505
Inactive10004-3.34154.8601-0.05933.13132.492711.5913-1.4902-13.7451.9094-3.61140.17755.8982-1.925-3.3415100040.1916
Inactive100044.68764.03720.43261.7117-5.36330.01244.09393.29011.8675-5.35829.301-3.3996-6.65394.687610004-0.8649
Inactive1000414.45021.1662-13.4728-0.06892.7591-5.585-15.2304-11.60378.2866-5.55088.036-4.6022-4.845814.450210004-3.7942
Inactive10-4.60461.1110.576731.0459-6.10640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.6548-7.6451-2.6127-0.4371-10.6818-11.93260.5693-21.22510.609-17.09791.011613.89869.803426.654810004-1.0538
Inconclusive15.166545.683610Partial curve; partial efficacy-4.81910.60.775941.0698-4.61382.20 0 0 0 0 0 0 0 0 0 0 0 0 0 032.1055-2.8274-2.73911.8943-2.4675-16.4634-3.3416-2.31647.09830.338415.525617.156218.43332.1055100040.1046
Inactive10-4.68594.50450.56518-4.235840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.1259-0.5226-4.0178-6.8476-0.1323-11.918-14.7798-1.343-0.6951-0.0477-3.8234-0.157915.36455.125910004-0.8015
Inactive10004-2.57192.1271-15.6379-9.9458-0.0566-1.3009-10.3345-4.73090.7930.4322-6.21176.0155-0.1149-2.571910004-0.2737
Inactive10-4.429110.3508160.584740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.03072.8758-1.4333-4.09618.1324-0.1788-1.8365-3.40460.96875.33925.74960.63436.788614.030710004-0.3011
Inactive10-5.88644.95490.460410-0.303340 0 0 0 0 0 0 0 0 0 0 0 0 0 014.81111.65651.78890.1435-7.595-1.069210.26810.1065-11.50277.37014.69215.95186.487814.811110004-6.6938
Inactive1000412.70575.94743.12190.9114-1.934610.27262.0269-12.6992-5.01885.3788-5.1369-2.868815.767612.705710004-1.5792
Inactive100048.0685-3.4653-4.85211.49384.676215.0539-6.5066-14.57680.9838-2.93245.02795.50265.54988.068510004-2.3647
Inactive100040.21273.5618-0.86484.668510.12697.869-0.11867.88796.91763.71724.3769.7145-1.76850.212710004-0.1916
Inactive1000415.68179.5665-3.95061.963.0139-1.30215.9929-15.24591.98272.56765.42287.37042.786215.681710004-3.34
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS233
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000042859 uM-Replicate_1W530-Activity at 0.0000098296 uM-Replicate_1W530-Activity at 0.0000389118 uM-Replicate_1W530-Activity at 0.0000921325 uM-Replicate_1W530-Activity at 0.0002143310 uM-Replicate_1W530-Activity at 0.0004423865 uM-Replicate_1W530-Activity at 0.00121 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-5.20073.990.3607-2.5677740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.945810.030110.74434.3442-5.05659.97422.951914.24288.764610.73796.49832.3813-4.5519-0.945810004.0000-0.4661
Inactive10-5.65074.95490.5456-1.9439840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.08469.49733.81968.4513-0.619110.36259.433713.778210.27034.69635.4408-1.6199-1.45995.084610004.00001.5918
Inactive10-5.55070.20.470118-0.201840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2543-1.00153.75646.89974.79742.8342.87626.5347.24690.758412.16298.90029.7511.254310004.0000-5.5377
Inactive100041.163-3.51611.707-1.8835-3.46991.9890.10351.2453-2.9592-3.6379-2.9446-1.8761-0.93791.16310004.00000.1358
Inconclusive1000416.859332.73635.020523.23553.332115.0249-2.90566.9949.49478.34391.2576-2.0333-2.290216.859310004.00009.1878
Inconclusive10004-2.1455-0.55639.41727.7352.03946.42493.62662.90958.6089-4.7033-4.009520.11873.2965-2.145510004.00007.8923
Inactive10004-3.66575.64289.1238-0.71545.00783.34610.6894.02219.965210.092117.6894-0.24811.5526-3.665710004.000014.7162
Inconclusive100044.2675-5.79323.71026.399110.69910.51886.8431-0.265818.58843.903414.16020.41198.98754.267510004.00006.5135
Inactive100049.866218.26245.804817.49314.15489.82548.16059.947216.279414.177417.85510.539517.09199.866210004.0000-5.4950
Inactive10004-5.329712.331.7312-5.499611.4558-3.72499.28072.31575.44163.66498.36633.099311.8517-5.329710004.0000-5.3240
Inconclusive70.04772.348410Partial curve; high efficacy; poor fit-4.15460.80.6385105.628933.28052.30 0 0 0 0 0 0 0 0 0 0 0 0 0 080.211934.473140.812939.568732.405624.682727.567430.391541.000332.340943.744858.28146.303280.211910004.0000-2.1350
Inconclusive19.093534.34910Partial curve; partial efficacy; poor fit-4.71914.95490.7411-28.10156.2475-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 11.53110.97148.54297.49310.6748-2.691-2.1743-2.26359.19559.26333.86910.8178-29.03671.53110-5.01914.95490.734118.5000-1.04734.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7941
Inactive10-5.33594.95490.4604141.095140 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7756-3.87228.9743-3.24331.4147-5.33746.5468-1.04071.0629-0.639615.012312.85582.944224.775610004.00004.5021
Inactive100047.41038.87323.5826-6.8276-3.40045.10857.125.99217.88590.76615.2069-2.5857-2.38937.410310004.0000-2.5566
Inactive10004-1.2866-1.8663.79256.244.97715.953813.60749.92898.28548.214414.36688.1213-0.9202-1.286610004.0000-3.9577
Inconclusive1000423.99170.9944-3.96381.687221.14372.265812.972312.03323.94191.4937-3.1913.4-3.920623.991710004.00006.2522
Inactive10004-4.56660.7965-6.9681-2.20180.034-1.99810.8299-0.3127-3.4977-3.3230.25471.8446-8.8778-4.566610004.00002.4663
Inactive10-7.02153.51170.347180.303440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5722-4.18564.19643.9575-4.3305-3.43177.7017.906311.39089.358710.9552-1.394.103110.572210004.00001.0750
Inactive10004-3.64221.972216.7669-4.364-3.7771-2.02811.2212-1.9042-4.0395-1.3596-5.395-2.4515-3.7855-3.642210004.00004.9536
Inactive1000416.4401-5.27783.8363-0.299718.8033-3.88715.63613.536316.4656.73621.28493.68095.811416.440110004.00004.3898
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:N/A
External ID: 2084-01_Activator_SinglePoint_HTS_Activity
Protocol: MITF Primary Screening Protocol
(TRPM-1 Promoter//Luciferase reporter assay)

Day 1, plate cells 2000 per well in 30 uL media (phenol red free DMEM/10% iFBS/Pen/Strep/L-Glutamine)

Day 2, pin 100 nL into 30 uL assay volume in white, opaque Corning 8867 barcoded 384 well plates. (will also require sentinel pinning with the positive control, parthenolide)
Incubate 24 hours at 37 degrees C in Liconic incubator

Day 3, add 20 uL 100% Promega Steady glo with Thermo Combi fluid transfer apparatus.
Shake 15 seconds on "big bear" plate shaker.
Incubate at RT for 5 minutes.
Read on Perkin-Elmer Envision with US LUM settings for 0.5 sec per well
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in increasing readout signal.
NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls Minus Inhibitors' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of 100.
Experimental wells values were scaled to this range.
PATTERN CORRECTION: The plate pattern correction algorithm 'Runwise Pattern (Multiplicative)' in Genedata (v7.0.3) was applied to the normalized plate data.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized and corrected sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set at 80.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at 100.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 3 (inconclusive) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

Samples passing PAR_T only were assigned an outcome of 3 (inconclusive) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_12.5uM_(%)REPLICATE_B_ACTIVITY_SCORE_12.5uM_(%)
0.80305.0220.742
0.9990-18.176-19.61
0.8620-7.599-1.979
0.7570-0.821-11.086
0.99028.58938.087
0.9960-6.025-4.98
0.937016.6197.568
0.73907.0240.325
0.9990-2.618-2.419
0.6330-4.7240.472
10-14.15-15.053
0.902.3270.809
0.84202.560.563
0.3510-7.41216.314
0.70-10.1310.108
0.9960-27.692-23.156
0.6980-11.060.138
0.989011.8468.737
0.71500.1018.982
10-95.322-95.121
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS837
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000042859 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000389118 uM-Replicate_1Activity at 0.0000921325 uM-Replicate_1Activity at 0.0002143310 uM-Replicate_1Activity at 0.0004423865 uM-Replicate_1Activity at 0.00121 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.81153.24171.7036-3.88633.70051.90923.46112.62383.42171.96184.5532-2.1817-2.0587-0.8115QC'd by SIGMAInactive0
Inactive00042.02641.27780.40633.132-0.96178.39740.80260.38625.08541.03870.96490.31392.19092.0264QC'd by Sigma DiscoveryCPRInactive0-6.03963.990.6227
Inactive0004-0.07830.8602-0.43130.77533.3389-7.07430.1475-4.9244-5.6061.28811.431-5.9165-1.58613.3747-0.0783QC'd by SIGMAInactive0-4.85182.12110.4048
Inactive0-8.53960.90.4382.5-17.2540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.4242-11.5665-3.6679-0.6129-7.17834.78830.4184-0.157710.703511.6402-3.9345-0.5512-6.24530.4242QC'd by SIGMAInactive0-7.93964.95490.4551
Inactive0004-5.3318-1.94410.4522-8.3321.0107-0.1156-10.7826-10.8532-4.24710.20287.2076-6.6671-8.3789-5.3318QC'd by SIGMAInactive0
Inactive00040.6118-3.3835-2.5203-9.6183-0.5168-7.3565-1.9351-3.59144.7435-5.2628-2.1247-4.3417-14.53680.6118QC'd by SIGMAInactive0
Inactive0004-5.3821-1.5125-3.5484-1.106-5.2777-3.6383-5.511-10.9006-6.9604-1.92230.6192-4.5677-4.7296-8.0223QC'd by SIGMAInactive0-8.2680.30.4015
Inactive00040.87320.4702-0.8794-0.6340.6861-1.04133.7723-12.8167-6.05652.7542-1.535-7.9041-5.49780.8732QC'd by SIGMAInactive0
Inactive0-6.83964.95490.55124-4.470340 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0676-1.3224-9.1419-1.1865-3.6159-5.2485-8.195310.19175.79951.09081.49983.96712.02971.0676QC'd by SIGMAInactive0-6.78964.95490.3599
Inactive0004-1.0220.210.2513-2.37471.3717-0.50383.9894-1.7888-6.79872.53691.01664.19945.5844-1.022QC'd by SIGMAInactive0-6.38964.95490.3471
Inactive0004-1.4059-3.132-7.66070.7238-4.33320.32411.33020.24797.5234-14.4771-13.01446.36361.2275-1.4059QC'd by RocheInactive0
Inactive0-4.33964.95490.3429-10.88620.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.07183.4287-0.5118-4.4669-2.302-2.17713.30782.8439-1.01244.2267-6.21353.9872-0.6916-9.0718QC'd by TCIInactive0
Inactive0004-0.68310.0297-0.9593-0.7386-2.2052-1.3291-4.3626-5.62091.9907011.30340.7086-3.1047-0.6831QC'd by SIGMAInactive0-5.48964.95490.3751
Inactive0-5.93961.78850.35820-3.229640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3463-2.7679-2.538-3.6541-2.975-8.1080.403-4.8358-1.7099-1.45512.2456-0.5792-0.4960.3463QC'd by SIGMAInactive0
Inactive0004-11.95511.4361-7.8259-8.6263-1.52171.5909-12.8729-11.017-6.8916-3.5531-4.5898-4.7446-6.1302-11.9551QC'd by LightBiologicalsInactive0
Inactive0004-9.9242-1.6531-3.70011.0424-7.9893.6152-5.8328-1.3701-2.0464-3.8438-5.7091-2.1285-5.1644-9.9242QC'd by SIGMAInactive0-4.33963.67720.3682
Cytotoxic40.77972.441840Partial curve; high efficacy-4.38963.92950.8982-74.5596-2.1178-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.8179-2.60644.2761-5.9881-1.3877-6.5057-2.59266.3601-8.70221.2883-0.5997-1.9403-18.4593-64.8179QC'd by TCICytotoxic51.337734.492820Single point of activity-4.28964.95490.8014
Inactive0004-14.5026-3.1743.642-4.3769-9.3023-7.6508-8.2832-19.8532-7.861711.7122-6.9451-14.94643.8797-14.5026QC'd by SIGMAInactive0
Inactive0004-2.2222-0.98421.4931-1.41171.1017-10.6336-4.34-12.0027-8.0387-2.805-8.872512.3039-3.6772-2.2222QC'd by SIGMAInactive0
Inactive0-7.33964.95490.52824.5-2.771840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0674-3.5855-4.2141.2009-4.39320.913.422214.0382.72535.26962.21886.31271.41211.0674QC'd by RocheInactive0-4.73964.0950.6096
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:N/A
External ID: GDH-TPI_INH_ABS_1536_1X%INH CSRUN
Protocol: Assay Overview:

The purpose of this biochemical counterscreen is to determine whether compounds act as absorbance assay artifacts or are non-selective. This assay also serves as a counterscreen for a set of ongoing high throughput primary experiments entitled, "Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of the aldolase of M. tuberculosis."

This counterscreen is similar in format to the aforementioned assay with the only two following differences: (i) the fructose-1,6-bisphosphate substrate is replaced with glyceraldehyde 3 phosphate, a product of its conversion by FBA and (ii) no (FBA) is used. The counterscreen hence recapitulates the two steps involved in the monitoring of FBA activity through the conversion of FB into the triose product glyceraldehyde 3 phosphate (G3P), which would be converted to dihydroxyacetone phosphate (DHAP) by the helper enzyme triose phosphate isomerase (TPI). A second helper enzyme, glycerophosphate dehydrogenase (GDH), converts the dihydroxyacetone phosphate to glycerol-3-phosphate with the concomitant oxidation of NADH to NAD, which is monitored by measuring the absorbance at 340 nm. In this new assay format, the A340 is independent of FBA activity, hence compounds that reduce absorbance at 340 nm are either absorbance artifacts or helper enzyme inhibitors that will not be pursued. Compounds are tested in singlicate at a final nominal concentration of 4.78 uM.

Protocol Summary:

Prior to the start of the assay, 5 uL /well of Buffer A (50 mM HEPES, 0.01% Triton X-100, 10% Glycerol, pH8.0) supplemented with 400 nM ZnCl2,240 uM NADH and the helper enzymes GDH-TPI (4 U/mL) was dispensed into all wells of a 1536-well plate except the "No enzyme" wells that contained the same supplemented buffer but no GDH-TPI enzymes. Next, 48 nL of test compounds were then delivered in each well using a PinTool. The assay was then initiated by dispensing 5 uL of Buffer A supplemented with 240 uM of the substrate glyceraldehyde-3-phosphate (G3P). Plates were incubated at room temperature for 20 minutes before A340 was measured using the EnVision plate reader (Perkin Elmer).

The percent inhibition for each compound was calculated as follows:

%Inhibition = 100 * ( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells treated with test compounds.
Low_Control is defined as wells treated with DMSO.
High_Control is defined as wells with no GDH-TPI enzyme.

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-13, and for inactive compounds 13-0.

List of Reagents:

ZnCl2 (Fisher Scientific, part Z33-500)
NADH (EMD Biosciences, part 481913)
GDH-TPI (Sigma, part G1881)
HEPES (EMD Biosciences, part EM-5310)
Triton X-100 (Sigma, part T8787)
Glycerol (Fisher, part AC327255000)
Glyceraldehyde-3-phosphate (Sigma, part D7137)
1536-well plates (Aurora, part 1091-11020-S)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that quench or emit absorbance within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR
Inhibition at 4.8 uM
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
11.19
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS898
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043397 uM-Replicate_1W530-Activity at 0.0000099416 uM-Replicate_1W530-Activity at 0.0000388206 uM-Replicate_1W530-Activity at 0.0000933245 uM-Replicate_1W530-Activity at 0.0002146562 uM-Replicate_1W530-Activity at 0.0004427766 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00957 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.768 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.987 uM-Replicate_1W530-Activity at 13.55 uM-Replicate_1W530-Activity at 30.33 uM-Replicate_1W530-Activity at 65.98 uM-Replicate_1W530-Activity at 172.8 uM-Replicate_1W530-Activity at 616.1 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.0766-0.0658-2.15293.9062-0.3999-1.37385.63961.2637-2.85641.76041.55167.3112-1.1534-0.076610004.0000-0.5396
Inactive10004-9.26574.0277-6.0118-0.0071-1.8112.0788-0.1063-9.81183.02231.6158-3.4131-0.3905-0.1348-9.265710004.0000-0.7395
Inconclusive17.752636.150110Partial curve; partial efficacy-4.75072.40640.95137.51.34992.20 0 0 0 0 0 0 0 0 0 0 0 0 0 030.754-1.3751.59181.76342.18881.4238-0.72522.56751.81642.88342.28283.111216.001330.75410-4.70072.40640.9040-16.0184-1.00004.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.5153
Inactive10004-0.8668-1.48543.1589-1.5267-0.3498-0.9828-1.6965-4.30540.34461.0195-3.8892-0.0431-3.4971-0.866810004.00002.1550
Inactive100040.4687-0.3692-2.2383-2.0699-1.1088-1.1038-1.892-3.7217-0.3761-2.9675-7.199-1.25980.5490.468710004.0000-4.3810
Inactive100040.4126-1.2865-0.5387-2.298-1.8546-1.5264-1.5856-1.7954-2.1107-10.0252-3.0851-2.8249-1.38430.412610004.00000.0966
Inactive10-8.75291.53860.542-3.90151040 0 0 0 0 0 0 0 0 0 0 0 0 0 10.10826.8455-0.6219-1.9403-3.2657-2.4784-1.636-6.3641-2.7947-6.0758-3.8759-3.1216-2.63750.108210004.0000-1.7240
Inactive10004-2.64841.2797-2.7761-6.4353-4.779-1.4021-0.3446-1.6237-1.1309-5.3966-0.90140-0.5502-2.648410004.00004.8834
Inactive10004-0.1792-0.474-1.4694-0.8953-0.4709-0.74150.1743-4.2804-1.4515-8.5725-1.40966.8573-0.4899-0.179210004.00000.3507
Inactive10-5.2314.95490.63782.5-6.309340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5172-6.7601-8.0367-0.7524-8.9539-6.7515-6.0875-9.8411-8.2478-4.204-0.20621.74341.04493.517210004.00007.8280
Inactive10-5.25464.95490.73888-2.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2916-1.1337-0.9738-3.7502-3.5438-3.92812.0571-0.3539-3.0856-2.45181.10275.54624.50711.291610004.00000.2257
Inactive10-4.71910.80.3767-22.1814-240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9565-2.4609-4.7653-0.7909-4.3968-2.1758-2.0522-3.5012-2.3448-13.94742.318-16.8178-12.5058-7.956510004.0000-0.5576
Inactive10-5.38594.95490.609313-3.112140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9382-2.1013-5.1202-0.9168-6.4291-0.2473-7.5114-1.6150.7413-1.600515.74921.42750.7564-0.938210004.00003.5229
Inactive10004-2.5193-0.5943-0.7208-2.3194-2.31182.0984-4.0928-2.1388-3.1827-4.05230.0794-0.2907-0.4065-2.519310004.00002.1690
Inactive10-4.97912.72020.55856-4.095340 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8855-0.6587-4.6588-0.4651-5.4882-3.2508-2.652-4.0762-6.6845-6.0914-4.67266.54320.29268.885510004.00008.4566
Inactive100040.3919-1.19260.06151.2782-3.2151-0.8299-0.6638-3.5934-2.2676-3.964912.1718-12.289-2.3960.391910-4.28643.13200.766711.50000.55584.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8922
Inactive100041.3115-1.013-0.5151-0.4031-1.1603-0.0285-0.1807-1.90091.5472-3.20528.574-14.1104-2.36981.311510004.00000.7374
Inactive100041.2453-0.1374-0.3605-3.4935-1.2563-2.4487-0.2616-0.72990.0304-4.47-0.75345.7775-0.09731.245310004.00001.2743
Inactive100040.0274-0.9052-3.7849-3.6459-0.6677-0.01462.1795-6.8978-0.8919-5.2845-0.8362-13.15210.1420.027410004.0000-2.5213
Inactive10004-2.4878-3.5001-2.6738-5.3379-5.5521-3.88740.4423-5.0105-3.9092-8.9672-0.5005-7.892-0.4544-2.487810004.00000.0360
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:hedgehog, isoform A [Drosophila melanogaster]
External ID: 2070-01_Inhibitor_SinglePoint_HTS_Activity
Protocol: Protocol:
ASSAY PROCEDURE FOR HEDGEHOG AUTOPROCESSING

Buffer A: 20 mM sodium phosphate, pH 7.5, 0.5 M NaCl

Buffer B: 20 mM sodium phosphate, pH 7.5, 0.5 M NaCl, 8 M urea
This is prepared by adding 48 g of urea (enzyme grade) to 50 ml of double-strength Buffer A and adjusting volume to 100 ml with H2O.


Buffer D: 20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, and 0.5 M arginine
(2.0 M arginine, pH 7.0, is prepared by dissolving 211 g of L-arginine hydrochloride (obtained from Research Organics) in 300 ml of H2O, adjusting pH to 7.0 with NaOH, and adjusting volume to 500 ml)



REAGENTS:
Urea - American Bioanalytical AB02100
Arginine Hydrochloride - American Bioanalytical AB000164
TCEP [Tris(2-carboxyethyl)phosphine hydrochloride] - Sigma C4706
DM-MEA [2-(Dimethylamino)ethanethiol] - Aldrich D141003 (very hygroscopic)
Cholesterol - Sigma C8667
FLAsH-EDT2-Invitrogen T34561

CELL DISRUPTION:

Suspend the cells from 50 ml of E. coli [Rosetta 2 (DE3)/pET45Dmel710#2] in 3 ml of Buffer A +
1 mM PMSF and disrupt by passing twice through the small French pressure cell. Centrifuge in 12 ml Sorvall tubes at 12,000 rpm for 30 min. and collect the pellet (inclusion bodies). The pellet is washed twice by resuspending in 4 ml of Buffer A + 1 mM PMSF and centrifugation at 12,000 rpm for 20 min. The pellet is then then resuspended in 3 ml of Buffer B + 1 mM PMSF to extract the inclusion bodies and centrifuged at 12,000 rpm for 20 min. Save the supernatant and extract the pellet a second time with 3 ml of Buffer B + 1 mM PMSF and combine the supernatants. Centrifuge the combined supernatants in the Sorvall at 18,000 rpm for 60 min to remove insoluble material and yield the solubilized inclusion bodies (IB). Save inclusion bodies at 4 degrees C after diluting about 10% with Buffer A to avoid crystallization of urea.

Typically, the protein concentration of the inclusion bodies is 1 mg/ml. The material is stable on storage at 4 degrees C for at least a month and can be kept frozen at -80 degrees C in 1 ml portions indefinitely.


Dilution Buffer:
297 ml of Buffer D
3 ml of 0.1 M TCEP
300 ml Final

Substrate mix
6.5 ml of 26 mM cholesterol in 95% EtOH
2.0 ml of 1% Triton X-100
41.5 ml of H2O
50 ml + 200 ml Dilution Buffer (cholesterol = 680 microM) - Dilute immediately before use

Control mix
0.8 ml of 1% Triton X-100
19.2 ml of H2O
20 ml + 80 ml Dilution Buffer (No cholesterol)

IB mix
13.2 ml Hedgehog protein ( approximately 1.65 mg/ml) [12 ml form prep of 10.05.11, 2 ml from prep of 10.05.10]
198 ml Buffer D (
room temp)
2.2 ml of 0.1 M TCEP
2.2 ml of 0.1 M DM-MEA
2.2 ml of 0.17 mM FlAsH
2.2 ml of H2O
220 ml final




Incubate at 25*C for 2 h. Dialyze against 3 X 1 liter Buffer D + 1 mM TCEP (10 ml of 0.1 M TCEP per liter) for 6 h - 14h. Recommended dialysis tubing: SpectraPor MWCO 8,000, flat width = 12 mM (VWR 25223-650). Readjust volume to 220 ml after dialysis.The dialyzed Hh Protein Cocktail can be stored at 4 degrees C for at least 5 days with negligible loss of activity. It should be stable at room temperature for at least 12 h.




Dispense 35 microl per well. Add IB mix first to entire plate. Wait 30 min before adding cholesterol, while control mix (35ul) is added to columns 23&24.

Then add substrate mix to columns 1-22, 40 min after adding protein. Fluorescence polarization was measured after 1 hour incubation at 25C using Tecan Safire 2 microplate reader (Tecan, Mannedorf, Switzerland) with excitation at 390 nm and emission at 550
nm.
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in increasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls Minus Inhibitors' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of -100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.7.0.3) was applied.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set to be three standard deviations above the mean neutral control value.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at -50.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 2 (active) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

tSamples passing PAR_T only were assigned an outcome of 2 (active) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_30.34uM_(%)REPLICATE_B_ACTIVITY_SCORE_30.34uM_(%)
0.9766013.0438.333
0.9926013.04316.667
0.959409.09116.667
0.9991018.18216.667
0.7071009.091
0.707108.3330
0.9594016.6679.091
0.95940-16.667-9.091
0.999108.3339.091
0.999108.3339.091
0.999108.3339.091
0.707108.3330
0.987802518.182
108.3338.333
0.948708.33316.667
1016.66716.667
1016.66716.667
0.948708.33316.667
0.9914021.73916.667
0.9991018.18216.667
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Luciferase [Photinus pyralis]
External ID: FLUC100
Protocol: NCGC Assay Protocol Summary:

Reagents: 50mM Tris acetate, pH 7.5; 10mM Mg acetate; 10uM D-luciferin (Sigma #L9504); 10uM ATP; 0.01% Tween-20; 0.05% BSA; 10nM P. pyralis luciferase (Sigma #L9506)
Control compounds used were two known firefly luciferase inhibitors (compounds (2) and (5) in Auld et al., 2010), and DMSO.

Assay Summary:
Three microliters containing firefly luciferase substrates in buffer (final concentrations: 50mM Tris acetate, pH 7.5, 10mM Mg acetate, 0.01% Tween-20, 0.05% BSA, 10uM D-luciferin, and 10uM ATP) are dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS), with a final compound concentrations ranging from approximately 60muM to 7pM. One microliter of firefly luciferase in 500mM Tris-acetate buffer was then delivered by FRD to each well for a final enzyme concentration of 10nM. Luciferase activity was then measured using a ViewLux CCD imager (PerkinElmer), with an average exposure time of 2-30 seconds (2X binning, medium/high gain).

Keywords: NIH Roadmap, MLPCN, MLSMR, qHTS, miR-21, firefly luciferase, FLuc, miRNA.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0007360000 uMActivity at 0.00368 uMActivity at 0.018 uMActivity at 0.092 uMActivity at 0.460 uMActivity at 2.300 uMActivity at 11.50 uMActivity at 57.50 uMCompound QC
Inactive40.6441.4220.8416.73120.91990.79760.644QC'd by "DPISMR"
Inactive42.34352.15212.96892.74162.84720.41112.3435QC'd by "DPISMR"
Inactive40.00150.3102-2.02731.33520.1332-0.30940.0015QC'd by "DPISMR"
Inactive40 0 0 0 0 0-0.17161.8652.02946.44762.37961.0274-0.1716QC'd by "DPISMR"
Inactive40 0 0 0 0 01.007-2.7011-0.17086.49912.00412.09671.007QC'd by "DPISMR"
Inactive40 0 0 0 0 0-1.11790.20496.1966-2.3909-2.16073.3301-1.1179QC'd by "DPISMR"
Inactive41.09492.87582.72841.6832.39681.14921.0949QC'd by "Enamine"
Inactive411.706114.523713.66923.910314.400215.012311.7061QC'd by "DPISMR"
Inactive4-0.88851.63653.59191.16423.17730.4167-0.8885QC'd by "Enamine"
Inactive41.4599-0.5382.53462.37523.35670.77211.4599QC'd by "DPISMR"
Inactive4-0.04271.21871.92551.54932.96770.0419-0.0427QC'd by "DPISMR"
Inhibitor37.93335.7734Partial curve; partial efficacy; poor fit-4.4214.95490.9772-33.77342-2.40 0 0 0 0 0-29.81120.92455.218-0.17231.08433.5778-29.8112QC'd by "DPISMR"
Inactive40 0 0 0 0 0-8.15691.33660.03721.43172.1732-0.2051-8.1569QC'd by "DPISMR"
Inactive40 0 0 0 0 0-2.06560.94922.39651.27311.48744.6957-2.0656QC'd by "DPISMR"
Inactive40.75931.31591.72011.71341.93143.16680.7593QC'd by "DPISMR"
Inactive40.762.95694.69134.99333.68572.58010.76QC'd by "DPISMR"
Inhibitor26.854526.7655Partial curve; partial efficacy; poor fit-4.5714.50450.9889-26.76550-2.40 0 0 0 0 0-26.0546-0.39711.5310.1508-1.9239-0.6216-26.0546QC'd by "Enamine"
Inactive41.72760.59362.47962.86622.87681.69721.7276QC'd by "DPISMR"
Inactive4-0.1439-1.24030.0246-0.25021.0119-0.5561-0.1439QC'd by "DPISMR"
Inactive40 0 0 0 0 0-3.34970.68682.3313-0.24711.6909-0.0071-3.3497QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:nuclear receptor coactivator 3 isoform a [Homo sapiens]
External ID: SRC3_INH_LUMI_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as inhibitors of the steroid receptor coactivator 1 (SRC3), also known as nuclear receptor coactivator 3 (NCOA3). In this assay, HEK293 cells are transfected with a GAL4-responsive reporter plasmid (pGL4.31, Promega) and an expression vector encoding SRC-3 fused to the DNA-binding domain of GAL4(pBIND-SRC-3). The ability of compounds to reduce coactivator transcriptional activity is assessed by measuring luciferase expression from the reporter gene plasmid. As designed, compounds that inhibit SRC3 ability to induce transcription will lead to a decrease in expression of the luciferase gene, resulting in reduced well luminescence. Compounds are tested in singlicate at a final nominal concentration of 3.6 uM.

Protocol Summary:

Seven million HEK293 cells were seeded into T-175 flasks containing 23 mLs of DMEM media supplemented with 10% v/v fetal bovine serum and 1% v/v Anti-Anti. Flasks were then incubated for 48 hours at 37 C, 5% CO2 and 95% relative humidity (RH). The day prior to the assay, cells were harvested using TrypLE, resuspended in fresh media at a density of 1 million cells per mL and seeded into new T-175 flasks (23 mL per flask). After allowed to attach for one hour at 37 C, 5% CO2 and 95% RH, cells were transfected with 1 mL of preincubated mix of serum-free OptiMEM containing 23 ug of the pGL4.31 reporter plasmid, 2.3 ug of pBIND-SRC3 vector, and 80 uL of transfection reagents. Twenty four hours post transfection, cells were harvested using 5 mL of TrypLE and resuspended at a concentration of 750,000 cells per mL in phenol-red free DMEM media supplemented as described above.

The assay was started by dispensing 5 uL of cell suspension into each well of a white, solid-bottom 1536-well plate using a flying reagent dispenser (3,750 cells per well). The first two columns received cells transfected with reporter plasmid and an empty pBIND vector as a control for background luminescence. Cells were then treated with 18 nL/well of test compounds, DMSO as a negative control (final concentration 0.36%), or Gossypol as a positive control (36 uM final) using a PinTool transfer unit (GNF). Plates were then placed in the incubator at 37 C, 5% CO2 and 95% RH. Twenty four hours later, plates were removed from the incubator and equilibrated to room temperature for 10 minutes. Luciferase activity was detected by adding 5 uL per well of ONE-Glo luciferase detection reagent. After a 15 minute incubation time, light emission was measured using the ViewLux plate reader (PerkinElmer).

The percent inhibition of each test compound was calculated as follows:

%_Inhibition = ( 1 - ( median_positive_control - test_compound ) / ( median_positive_control - median_negative_control ) * 100

Where:

Test_Compound is defined as wells containing test compound treated cells.
Positive_Control is defined as wells containing Gossypol treated cells.
Negative_Control is defined as wells containing DMSO treated cells.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally active compounds. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater %inhibition than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-64, and for inactive compounds 64-0.

List of Reagents:

HEK-293 cells (ATCC, part CRL-1573)
DMEM media (Invitrogen, part 11965)
Fetal Bovine Serum (Hyclone, part SH30088.03)
Anti-Anti (Gibco, part 15240)
TrypLE (Invitrogen, part 12604)
T-175 flasks (Falcon, part 353112)
pGL4.31 (Promega, part C935A)
pBIND-SRC3 (Assay Provider)
TransIT 293 transfection reagent (Mirus Corporation, part MIR-2700)
ONE-Glo luciferase reagent (Promega, part E6130)
White, solid-bottom 1536-well plates (Greiner, part 789173)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, cytotoxic compounds, compounds that perturb the UAS/GAL4 reporter system, and compounds that quench, inhibit, stabilize, or emit luminescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3.6 uM
20.65
20.65
20.65
20.65
20.65
20.65
20.64
20.64
20.64
20.64
20.64
20.64
20.63
20.63
20.63
20.63
20.63
20.63
20.63
20.63
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:nuclear receptor coactivator 1 isoform 1 [Homo sapiens]
External ID: SRC1_INH_LUMI_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as inhibitors of the steroid receptor coactivator 1 (SRC1), also known as nuclear receptor coactivator 3 (NCOA1). In this assay, HEK293 cells are transfected with a GAL4-responsive reporter plasmid (pGL4.31, Promega) and an expression vector encoding SRC1 fused to the DNA-binding domain of GAL4 (pBIND-SRC-1). The ability of compounds to reduce coactivator transcriptional activity is assessed by measuring luciferase expression from the reporter gene plasmid. As designed, compounds that inhibit SRC1 ability to induce transcription will lead to a decrease in expression of the luciferase gene, resulting in reduced well luminescence. Compounds are tested in singlicate at a final nominal concentration of 3.6 uM.

Protocol Summary:

Seven million HEK293 cells were seeded in T-175 flasks 23 mL of DMEM media supplemented with 10% v/v fetal bovine serum and 1% v/v Anti-Anti. Flasks were then incubated for 48 hours at 37 C, 5% CO2 and 95% relative humidity (RH). The day prior to run the assay, cells were harvested using TrypLE, resuspended in fresh media at a density of 1 million cells per mL and seeded into new T-175 flasks (23 mL per flask). After being allowed to attach for one hour at 37 C, 5% CO2 and 95% RH, cells were transfected with 1 mL of preincubated mix of serum-free OptiMEM containing 23 ug of pGL4.31 reporter plasmid, 2.3 ug of pBIND-SRC1 vector and 80 uL of transfection reagents. Twenty four hours post transfection, cells were harvested using 5 mL of TrypLE and resuspended at a concentration of 750,000 cells per mL in phenol-red free DMEM media supplemented as described above.

The assay was started by dispensing 5 uL of cell suspension into each well of a white, solid-bottom 1536-well plate using a flying reagent dispenser (i.e. 3,750 cells per well). The first two columns received cells transfected with the reporter plasmid and an empty pBIND vector as a control for background luminescence. Cells were then treated with 18 nL/well of test compounds, DMSO as a negative control (final concentration 0.36%) or Gossypol as a positive control (36 uM final) using a PinTool transfer unit (GNF). Plates were then placed in the incubator at 37 C, 5% CO2 and 95% RH. Twenty four hours later, plates were removed from the incubator and equilibrated to room temperature for 10 minutes. Luciferase was detected by adding 5 uL per well of ONE-Glo luciferase detection reagent. After a 15 minutes incubation time, light emission was measured with the ViewLux reader (PerkinElmer).

The percent inhibition of each test compound was calculated as follow:

%_Inhibition = ( 1 - ( median_positive_control - test_compound ) / ( median_positive_control - median_negative_control ) * 100

Where:

Test_Compound is defined as wells containing test compound treated cells.
Positive_Control is defined as wells containing Gossypol treated cells.
Negative_Control is defined as wells containing DMSO treated cells.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally active compounds. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-63, and for inactive compounds 63-0.

List of Reagents:

HEK-293 cells (ATCC, part CRL-1573)
DMEM media (Invitrogen, part 11965)
Fetal Bovine Serum (Hyclone, part SH30088.03)
Anti-Anti (Gibco, part 15240)
TrypLE (Invitrogen, part 12604)
T-175 flasks (Falcon, part 353112)
pGL4.31 (Promega, part C935A)
pBIND-SRC1 (Assay Provider)
TransIT 293 transfection reagent (Mirus Corporation, part MIR-2700)
ONE-Glo luciferase reagent (Promega, part E6130)
White, solid-bottom 1536-well plates (Greiner, part 789173)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, cytotoxic compounds, compounds that perturb the UAS/GAL4 reporter system, and compounds that quench, inhibit, stabilize, or emit luminescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3.6 uM
18.31
18.31
18.31
18.31
18.31
18.31
18.31
18.3
18.3
18.3
18.29
18.28
18.28
18.28
18.28
18.27
18.27
18.27
18.27
18.27
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NMMLSC 靶标:N/A
External ID: UNMCMD_DSG_PRIMARY_MLPCN
Protocol: Protocol:
1) Protein G beads (1.06 million beads per 384 well plate) are coupled with the DSG3 antigen by overnight incubation with a cell lysate containing an Fc-DSG3 construct.
2) Coupled beads are used at 3000 beads per well
3) scFv-GFP reagent is diluted in Assay buffer (PBS with 1mM CaCl2, 0.05% BSA, 0.01% Na Azide), added to 382 well assay plates, and incubated with a 20 microM solution of test compounds for 60 minutes at RT.
4) Vehicle control (2%DMSO) and Blocking control (1/40 dilution of soluble DSG3 antigen) are similarly incubated with scFv-anti-DSG3-GFP
5) Pre-coupled beads are added to each well and plates are incubated for 60 minutes with rotation
6) scFv-anti-DSG3-GFP binding to beads is detected using flow cytometry and reported as the Median Channel Fluorescence

Calculations:
Z and Z' values were calculated individually for all plates, most plates passed a Z'>0.3.
An average response value was computed for each plate. Compounds were considered active if the associated well fluorescence was greater than 3SD below the Average Median Fluorescence of the individual plate.

dif = PLATE_CUTOFF - RESPONSE

If diff < 0
Then PUBCHEM_ACTIVITY_SCORE = 0
Else If diff > 100
Then PUBCHEM_ACTIVITY_SCORE = 100
Else
PUBCHEM_ACTIVITY_SCORE = diff

If (PUBCHEM_ACTIVITY_SCORE > 0) AND (RESPONSE > 0)
THEN PUBCHEM_ACTIVITY_OUTCOME = 2 (or ACTIVE)
If (PUBCHEM_ACTIVITY_SCORE > 0) AND (RESPONSE = 0)
THEN PUBCHEM_ACTIVITY_OUTCOME = 3 (or INCONCLUSIVE)
Else
PUBCHEM_ACTIVITY_OUTCOME = 1 (or INACTIVE)
Comment: This reference is not indexed in PubChem
1. Stanley, J.R. 2008. Pemphigus. In Fitzpatrick's Dermatology in General Medicine. K.Wolff, Goldsmith,L.A., Katz,S.I., Gilchrest,B.A., Paller,A.S., and Leffell,D.J., editors. McGraw-Hill. New York. 459-468.
RESPONSEPLATE_CUTOFFZPRIME
107.4689.770.84
95.6339.630.91
102.0262.570.9
103.1380.180.87
106.3888.260.84
101.7376.650.76
97.2584.190.88
92.8889.450.87
99.4589.890.96
98.6782.480.74
119.5786.440.93
99.0781.460.92
104.5279.530.9
103.3297.020.91
104.152.740.69
102.4859.60.89
105.15-50.620.9
98.2287.520.84
86.7875.40.82
98.6488.740.93
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2293
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL stimulation mix containing 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000138057 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003003888 uM-Replicate_1W530-Activity at 0.0006194162 uM-Replicate_1W530-Activity at 0.00172 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inconclusive10004-1.9035-1.1923-2.0332-1.0619-12.6616-0.78820.0664-11.7887-6.4513-11.6244-1.9076-2.0225-3.2172-1.90350Single point of activity-5.61024.95490.9089-45.54365-30 0 0 0 0 0 0 0 0 0 0 1 1 1 126.2694
Inactive10004-1.20222.7609-0.01530.9955-0.41571.63592.32520.5928-0.99092.84790.1279-0.03861.8432-1.202210004-31.8285
Inhibitor0.994556.503510004-2.90612.33111.736-3.60126.00595.10040.6447-1.71252.76160.832-1.74680.48220.191-2.90610Single point of activity-6.00242.25260.6374-44.503512-31 0 0 0 0 0 0 0 0 0 1 1 1 1 18.1326
Inconclusive10004-1.3710.9506-2.91191.52635.1535.55271.52731.54971.7024.269902.5531-6.3366-1.37110004-25.7768
Inactive10004-4.2769-0.95591.72782.6067.9793-4.5417-5.96084.89575.48863.60130.2343-3.1649-0.1676-4.276910004-8.7462
Inhibitor8.758121.9554100041.30884.730914.16229.43255.624-1.95912.73144.32472.41837.8238-5.8845-5.16396.60721.30880Single point of activity-5.05761.10.6955-89.934132.0212-30 0 0 0 0 0 0 0 1 0 0 0 0 1 1-23.4699
Inconclusive0.002425.78310Complete curve; partial efficacy; poor fit-8.61330.80.8235-3.7909-29.57391.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4664-19.6302-7.473-8.9859-9.0898-8.3146-0.2424-6.5275-6.0557-3.3866-1.82-2.8939-4.0012-2.466410004-30.4385
Inactive10004-7.3264-1.5887-10.9052-0.9831-6.53-5.410.9435-5.6079-0.699-2.0867-3.2569-4.2536-2.16180.5621-7.326410-7.92771.80790.6047-24.965740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-31.1667
Inconclusive10004-0.76813.03751.73091.12096.2561-0.0974-8.24190.864-0.54561.50994.4639-1.16054.7076-0.76810Single point of activity-4.95763.1320.706-69.1601-0.5-30 0 0 0 0 0 1 0 0 0 1 1 0 1 1-35.5326
Inconclusive10-5.8521.69240.3729-0.5701440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.18373.34480.978.50642.5766.04151.76024.88511.9267-0.2988-0.0183-1.0279-1.3405-0.183710-8.8024.95490.41826-43.08340 0 0 1 0 0 0 0 0 0 0 0 0 0 022.5365
Inconclusive10-9.12574.44950.3776-1-17.747540 0 0 0 0 0 0 0 0 0 0 0 0 0 02.0705-13.4218-2.2278-1.534-1.45313.8095-2.4909-1.0374-13.5396-0.16050.0263-0.09952.04422.0705100046.6627
Inconclusive10Partial curve; partial efficacy; poor fit-4.15594.95490.9512-25.9952-1-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.246-1.2286-0.8428-1.2278-0.5805-1.8719-0.06640.8961-0.8452-1.9038-2.1419-3.3814-0.974-21.24610-5.25594.95490.5517-28.362-240 0 0 0 0 0 0 0 0 1 1 0 0 0 1-3.0491
Inconclusive10004-2.6403-1.5203-3.2668-0.3318-5.31293.2585-4.0841-4.30851.19516.0144-4.8227-2.25281.5709-2.64030Partial curve; high efficacy; poor fit-5.16334.95490.4313-80.8838-1.5-2.30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-1.3949
Inactive10004-0.26721.230113.62434.24763.99616.594517.55362.17369.11160.1969-3.48061.5252-2.0777-0.267210-5.31244.95490.3735-19.39133.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.3739
Inactive10004-5.77735.11124.0288-1.9434-1.021412.92192.34717.4846-2.0121.291-2.74985.90195.369-5.777310004-4.4961
Inconclusive10004-15.4564-4.51941.21191.7588-11.93060.5255-1.2623.2933-2.6412-3.3809-1.071-2.7851-1.8097-15.456410-4.66420.70.437326.1319-6.859441 0 0 0 1 0 0 0 0 0 0 0 0 0 10.7866
Inactive100045.20961.56415.30634.99462.482-1.21514.35076.00556.2785-0.47860.86696.1344.32315.209610004-35.4391
Inactive100042.47121.4625-2.9807-1.69247.24483.0542-12.2145-8.3996-2.4864.052-1.4266-1.5593-0.16762.4712100043.4572
Inactive10-4.91021.46410.523614.5-0.475640 0 0 0 0 0 0 0 0 0 0 0 0 0 013.887.5564-7.4796-3.3029-4.4182-3.7928-2.6927-0.11982.6654-1.01760.301216.57859.432213.88100043.7428
Inactive100040.5160.0357.1699-4.87981.4861-5.9734-8.5349-6.6743-1.7256-1.1817-1.1379-5.50792.8730.51610004-5.7554
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2713
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL agonist-stimulation mix containing 1nM Isoproterenol HCl, 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inhibitor26.603267.916510004-6.3959-9.65890.68632.7866-13.8272-6.7622-5.1896-0.7481-5.27594.03470.82940.1619-7.9826-6.39590Partial curve; partial efficacy-4.57512.04790.7981-71.9165-4-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-55.9973
Inactive10-4.62514.44950.3528-7.16493.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.38749.90032.8880.83753.8232-0.0972-3.85071.63986.05136.86712.68588.8472-0.8502-6.3874100041.575
Inactive10-6.97511.47810.3563-3.5961240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.93160.12450.04624.37542.76350.5086-0.9132-2.76892.6163-8.8301-3.1415-5.9818-0.09820.9316100041.7546
Inactive10004-0.2652-5.20890.1059-0.2104-5.15230.33386.5915-0.1964-2.77990.7841-0.7171-11.48410.0954-0.265210004-13.1319
Inactive100042.5869-2.9649-3.11563.2094-2.83759.1891-4.0873-2.306-3.35572.25610.25920.4568-2.76022.586910004-1.7942
Inactive10-8.42514.95490.42-1.5675840 0 0 0 0 0 0 0 0 0 0 0 0 0 13.10992.05513.45141.5277-1.18820.19451.17012.6784-0.2053-6.4479-0.458-3.6987-4.65953.109910-6.57510.50.3897-7.94783.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9647
Inactive100041.98244.9364-3.0777-2.52245.8788-4.393-2.1514-6.5660.2639-2.3165-0.97250.1618.67231.9824100046.8262
Inactive100043.1910.64224.5969-8.3735-6.2557-10.06561.9483-0.0245-0.5998-6.34343.4655-0.97126.44013.19110-6.42514.95490.47171-6.555840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4044
Inactive100043.06910.94732.7335-0.3539-2.50762.6313-2.14111.34421.3076-1.59431.5055-0.4395-0.98173.0691100041.074
Inactive100040.03460.7513-5.05642.3416-3.78150.6279-8.57720.96422.5971-5.43511.94880.0125-4.35290.0346100041.8201
Inactive100040.6895-3.70214.9864-1.54015.41435.0376-4.7424-5.3192-0.37944.4337-3.11858.58982.10140.6895100040.0062
Inactive100041.35410.6932-6.5104-4.10014.12961.40140.1852-2.5615-2.9103-6.16262.11950.64771.75491.354110004-0.079
Inactive10004-0.9612-2.32050.75015.3012-0.3654-0.41856.8872-1.988210.93541.3283-3.35076.4187-0.5006-0.961210-8.87513.06540.39511.5-6.166340 0 0 0 0 0 0 0 0 0 0 0 0 0 05.4117
Inactive10-4.97510.70.3315-10.872-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.76180.98150.1-0.85683.8492-10.310.16961.4622-0.195-5.3525-2.1777-5.7002-7.2375-7.761810-7.52514.95490.3969-2.9301540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.0376
Inactive10-5.12514.95490.8156-9.2611-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.12810.0145-0.6779-1.47220.3898-1.23510.5729-4.44590.86280.7235-0.3998-7.3742-9.8009-8.128110004-2.0593
Inactive100046.04370.32725.2199-1.386516.5133-4.78731.16280.41731.29560.90511.13123.78936.19046.0437100040.8526
Inactive10004-5.2833-3.6332-8.5443-7.987-8.28162.6995-7.1202-2.40580.91532.5108-1.3669-7.4886-7.4328-5.2833100046.8517
Inhibitor29.8493106.094510-5.47512.84730.42146.5-2.542840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.2442-0.53315.2895-5.86780.6544-0.4618-5.09910.1718-8.184-9.20241.59976.35576.1854-3.24420Partial curve; high efficacy-4.52512.12110.9077-108.0945-2-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.8897
Inactive10-6.02514.95490.40980-4.031340 0 0 0 0 0 0 0 0 0 0 0 0 0 02.6436-7.1138-4.8994-1.2953-3.42690.0695-5.181-8.7761-5.8014-2.75760.2413-0.1351-2.45232.643610004-7.8883
Inactive10004-5.3863-7.35993.98542.9754-2.40971.18239.4234-0.41260.864-0.3003-2.479-0.03810.1317-5.386310004-9.0143
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2945
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of mixture of NKH477 (final concentration at 200 nM) and quinpirole (final concentration at 12 nM) was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060292 uM-Replicate_1W530-Activity at 0.0000139277 uM-Replicate_1W530-Activity at 0.0000552087 uM-Replicate_1W530-Activity at 0.0001297661 uM-Replicate_1W530-Activity at 0.0003003480 uM-Replicate_1W530-Activity at 0.0006206701 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.348 uM-Replicate_1W530-Activity at 1.074 uM-Replicate_1W530-Activity at 3.280 uM-Replicate_1W530-Activity at 8.379 uM-Replicate_1W530-Activity at 18.94 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 242.9 uM-Replicate_1W530-Activity at 865.8 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100043.78813.72091.98610.20610.59235.59482.53080.60822.30311.88620.3033-2.23441.87823.788110004-12.0188
Inactive100040.30120.52940.6626-2.6038-0.5572-0.6631-4.33661.0325-2.759-0.3338-0.3287-1.63422.49720.3012100042.5444
Inactive10004-6.3367-0.20894.28190.94444.1311-1.1259-2.3025-0.8518-3.0168-0.69982.3696-1.04735.4453-6.336710-4.87513.51170.6776-24.2714-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.914
Inactive10004-1.1765-2.02963.5024-1.9703-0.15791.9613-0.75732.76970.8721.72771.1044-0.05681.933-1.176510-6.12514.95490.4361-5.3789240 0 0 0 0 0 0 0 0 0 0 0 0 0 116.187
Inactive10-4.44014.95490.7066-19.0899240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.90474.8233-2.51545.04834.70586.1601-0.2063-0.8092-0.6546-4.17011.85590.3717-17.5749-0.904710-4.49014.95490.471515.5-4.348640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.0917
Inconclusive10-6.62354.95490.7986-0.6511040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.63988.774811.18327.61489.427810.847712.24230.7218-1.8373-2.18071.01625.3861-1.696-3.639810004-1.5758
Inactive100041.33252.41660.0324-1.17531.0360.22312.63193.94840.94140.00221.27583.2279-2.80021.332510004-3.3592
Inactive10-6.37992.72020.319-1.29553.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.3155.53032.4743-0.4098-0.05774.777410.7719-2.01031.7767-1.0637-1.2042.5912-3.5795-3.31510-6.32994.95490.42623.5-6.413140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.295
Inactive100041.11512.34553.30752.55170.31210.86413.3572-5.8070.82230.74510.4398-3.3457-5.97791.115110-7.08462.04790.54874-12.505140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.5005
Inactive100041.63771.2371-1.25830.3296-1.6140.7175-1.114-0.0071-2.3580.54470.1386-1.0325-0.62621.637710004-2.264
Inactive100041.1729-5.37470.0618-1.16140.2075-0.5657-2.68830.98772.79770.48074.20440.5734-4.58271.172910-7.72874.95490.3377-4.06432.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4636
Inhibitor50.887851.364110004-0.0970.4130.80160.55140.49890.17153.02080.70020.7634-4.9454-3.23730.4082-4.1558-0.0970Partial curve; partial efficacy-4.29343.06540.7755-53.8641-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.2455
Inactive100047.09728.61190.86441.2866-1.15580.06177.65980.00716.608-1.8979-2.1702-0.918410.71347.097210-4.66014.44950.5285-18.6347-340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5019
Inactive100040.4698-1.0082-3.0359-1.3764-2.8847-2.1219-1.72584.0502-6.0703-2.72140.76450.6902-0.23090.469810004-4.9773
Inactive100045.8424.59930.09510.5509-0.07364.4281-2.8904-1.95170.0719-0.5266-2.90590.46610.03965.84210-4.15331.210.5077-31.931240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2758
Inconclusive100042.20030.65450.18076.1358-0.38062.10074.9512-0.01961.9422-1.56120.41822.5985-2.1292.200310-6.56052.72020.4244-1.5-9.440940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.2578
Inhibitor31.4373115.3525100049.71694.21783.58235.13815.09542.57424.22143.54180.04322.4418-1.71227.3565-0.25439.71690Partial curve; high efficacy-4.50261.24750.9516-117.8525-2.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.3794
Inactive100041.7529-5.7942-2.1210.23431.62890.87140.2124-5.88470.01861.5276-1.9768-1.2986-3.43591.752910-8.09594.95490.48860.5917840 0 0 0 0 0 0 0 0 0 0 0 0 0 00.6765
Inactive100043.39870.6520.80240.3115-3.13092.1040.4118-2.7174-3.73120.0892-0.14594.0124-0.74333.398710-8.74514.95490.45570.928714.540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.1127
Inactive100045.282.1409-0.18040.24510.4128-3.92832.74470.34230.07910.359-0.25380.8178-2.33135.2810004-1.3082
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2180
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of NKH477 at 200nM was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006189798 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-9.17434.95490.4482-3.18846.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.07816.0843-0.8272-3.4248-7.0165-0.7165-1.5939-6.0807-6.8337-3.16772.3771-1.0033-5.7858-1.5510004-2.7583
Inactive10-4.56371.86170.317890.084640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0842-0.0855-0.2953-0.78052.34661.2131-0.54523.1167-3.3842-0.91893.75641.40566.4780.084210004-4.2236
Inactive100042.61982.3466-0.37735.5914.99152.11680.87533.1726-0.17420.9304-1.192-0.56531.70682.619810004-6.2418
Inactive100046.3560.92680.5680.6444-3.3685.672.3853-0.05552.7361-3.48357.347-3.04965.74596.356100043.4789
Inactive100041.38231.31710.97261.5261-8.2713-38.61011.4699-0.6371-5.1128-8.1546-1.1688-0.5786-0.66451.3823100048.8154
Inactive10004-2.5144-2.361-1.80391.85040.1129-6.2676-1.336-3.9127-3.9292-2.7130.026-2.79-2.1424-2.514410004-9.9999
Inactive100048.63938.07697.9985-2.61410.32086.27480.56646.16683.97512.40730.27918.65336.08258.6393100040.6824
Inactive10004-4.5511-0.5715-12.6079-5.3348-1.7778-1.64430.7428-13.8301-1.3699-2.6117-9.8602-7.4651-3.7149-4.5511100044.8975
Inactive10004-8.9924-2.5393-12.2689-12.3285-8.4096-5.3726-7.3661-8.2488-6.5273-10.2917-10.0818-0.9401-19.8028-8.992410-4.56374.95490.6441100.364840 0 0 0 0 0 0 0 0 0 0 0 0 0 08.3824
Inactive100040.5065-4.7724-1.7416-5.05921.11050.443-0.1512-1.416-1.4307-0.5117-7.58251.11541.19672.93930.5065100042.402
Inactive100040.07942.87210.18864.94540.2886-2.1392-1.7328-1.01662.15434.9444.9611.73843.84360.079410-5.06374.95490.4347-3.07543.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.2874
Inactive10-4.61644.0950.4209-7.778140 0 0 0 0 0 0 0 0 0 0 0 0 0 12.11662.02-0.42232.25972.48460.06621.20842.5829-1.68581.7929-0.6289-1.1-6.89832.116610-4.11644.95490.5915-20.3885-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3238
Inactive10004-7.0632-0.8623-1.7916-4.2652-5.9669-19.4504-1.91220.824-2.2999-5.5153-0.4675-5.37812.0763-7.063210-8.81374.95490.73241-15.784740 0 0 0 0 0 0 0 0 0 0 0 0 0 03.2717
Inactive100045.45724.7104-1.6933-3.19594.97480.59361.7222-0.1931.27552.5585-4.68520.39195.48635.457210-9.04334.95490.6699-0.51411.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4299
Inactive10004-5.15337.6944-0.2819-6.74360.13834.2317-8.8165.28882.3311.64635.25816.3561-1.5635-5.153310-8.71374.44950.67941.5-14.151240 0 0 0 0 0 0 0 0 0 0 0 0 0 01.5537
Inactive100047.48515.0097.9161-5.82395.4781-0.20210.73765.95164.1964-6.02863.1953-2.5872.51947.4851100042.0117
Inactive100047.63123.15953.60054.23419.422-0.7563.62193.93153.42863.89981.27179.0227-0.49517.631210004-6.9865
Inactive10-5.36374.95490.3650.132640 0 0 0 0 0 0 0 0 0 0 0 0 0 111.41172.26859.495711.56072.32788.75936.01856.48955.66755.3341-2.80674.5233-1.542111.411710004-1.6128
Inactive100042.8507-1.44118.21990.12610.2712-2.1386-1.41324.99742.20190.50950.32360.58160.98078.83382.8507100040.3148
Inactive10004-3.5331.7914-3.9103-4.2814-4.8026-0.23944.0174-2.4595-1.52260.851.611-2.87492.3635-3.53310004-4.1257
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1834
Protocol: Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.27-0.01710.2452-0.00120.080.07230.2279-0.64050.02840.0796-0.0665-0.0639-0.02560.27QC'd by SigmaAldrichInactive0
Inactive00040.3979-0.06510.78140.003-0.08590.1712-0.03250.09370.0666-0.442-0.6501-0.7181-1.19180.3979QC'd by Toronto ResearchInactive0
Inactive00040.50960.13750.02540.15070.01870.023-0.0882-0.04940.26750.23570.15260.0353-0.51360.5096QC'd by SigmaAldrichInactive0
Inactive00042.53080.77180.56770.1541-0.18960.0586-0.0992-0.19140.07380.69750.14260.09660.34082.5308QC'd by SIGMAInactive0
Inactive0004-1.14720.10470.25460.15670.13560.05240.35320.1530.0574-0.6714-0.19020.1471-1.2293-1.1472QC'd by SIGMAInactive0
Inactive00040.14630.0224-0.33040.05520.09030.0693-0.08240.1615-0.03260.09990.3798-0.07420.35760.1463QC'd by SIGMAInactive0
Inactive0004-0.0699-0.94060.80630.77990.03390.7610.03490.21810.49060.0890.2004-0.0501-0.0028-0.0699QC'd by SIGMAInactive0
Inactive00041.83420.1116-0.00320.11720.23360.2218-0.15310.0723-0.0177-0.04750.0390.36720.25951.8342QC'd by SigmaAldrichInactive0
Inactive00041.2961-0.0487-0.113-0.27430.0322-0.18530.2616-0.01810.4137-0.05260.35890.45560.61241.2961QC'd by SigmaAldrichInactive0
Inactive0004-0.17021.55020.53860.099-0.1571-0.2841-0.4676-0.23710.2585-0.29890.42120.2244-0.329-0.1702QC'd by SIGMAInactive0-4.24844.95490.9849
Inactive00040.617-0.0348-0.0116-0.15060.12690.09220.04280.13080.67190.54110.05040.04340.07380.617QC'd by SigmaAldrichInactive0
Inactive00040.08250.10830.13780.04780.2340.03580.0664-0.12370.0503-0.01640.11520.24270.00820.0825QC'd by SIGMAInactive0
Inactive00040.29450.04740.51170.20190.25530.09380.3703-0.06840.1512-0.01270.2949-0.07560.07070.2945QC'd by SigmaAldrichInactive0
Inactive0004-0.47420.19480.86240.64810.36120.4680.4992-0.19240.7415-0.0520.3014-0.4759-0.7733-0.4742QC'd by SIGMAActivator4.888238.3142Complete curve; partial efficacy-5.31084.95490.9876
Inactive0004-0.10730.05280.15780.0556-0.06520.094-0.0707-0.09840.15540.01480.06-0.683-0.0854-0.1073QC'd by SIGMAInactive0
Inactive0004-0.38280.7081.10930.27520.50230.35130.5920.2070.31280.31150.00490.15090.0186-0.3828QC'd by SIGMAInactive0
Inactive00043.19140.05370.0627-0.0199-0.91560.34450.1644-0.0051-0.06990.12160.44840.16630.14663.1914QC'd by Spectrum ChemicalInactive0
Inactive0-8.86033.990.97980.24231740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.08198.09170.91440.3470.2061.69190.27670.2627-0.1985-0.0993-0.2147-0.0596-0.0858-0.0819QC'd by SIGMAInactive0
Inactive00040.11330.20950.15290.2804-0.00250.29590.57160.22840.33210.03070.11970.07720.34590.1133QC'd by SigmaAldrichInactive0
Inactive00040.53410.02420.21240.18710.04730.10960.04040.0920.12340.01120.1629-0.07080.20290.5341QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1997
Protocol: Tox21 Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of acetylcholine at 50nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039960 uM-Replicate_1Activity at 0.0000091663 uM-Replicate_1Activity at 0.0000362847 uM-Replicate_1Activity at 0.0000862850 uM-Replicate_1Activity at 0.0001998674 uM-Replicate_1Activity at 0.0004124603 uM-Replicate_1Activity at 0.00113 uM-Replicate_1Activity at 0.00347 uM-Replicate_1Activity at 0.00893 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.045 uM-Replicate_1Activity at 0.102 uM-Replicate_1Activity at 0.232 uM-Replicate_1Activity at 0.710 uM-Replicate_1Activity at 2.174 uM-Replicate_1Activity at 5.582 uM-Replicate_1Activity at 12.62 uM-Replicate_1Activity at 28.26 uM-Replicate_1Activity at 61.51 uM-Replicate_1Activity at 159.9 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.1781-14.6077-15.74035.874-6.19418.893-5.649710.7344-0.67673.7136-6.5739-2.1499-21.2783-2.1781QC'd by SIGMAInactive0
Inactive0-6.1260.30.4906-11.7304-33.739340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5369-31.6558-25.1796-28.7381-31.0798-26.2723-27.0785-30.5027-26.1541-8.1086-12.2914-19.9415-24.8788-16.5369QC'd by SIGMAInactive0
Inactive000415.11824.3534-3.1877-2.3826-5.7413-2.494211.75430.97083.76215.91024.486711.0592-5.946515.1182QC'd by SIGMAInactive0
Inactive0-8.52620.80.37567.5-8.95740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.0338-3.64071.60920.62293.187712.91231.74593.92468.020910.518311.639515.6309-5.7975-7.0338QC'd by SIGMAInactive0
Inactive0-6.0263.990.37841.5-16.326140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.701-23.9593-2.61690.34194.1756-23.8273-28.1884-27.1927-13.1416-3.4634-3.930911.7786-7.39137.701QC'd by SIGMAInactive0-7.4761.3310.4129
Inactive0-8.87624.95490.4467-2.89869.540 0 0 0 0 0 0 0 0 0 0 0 0 0 11.2264.0632-6.2638-6.4961-4.2253-3.5816-3.9002-1.843-3.68491.19333.89413.4558-6.99891.226QC'd by SIGMAInactive0
Inactive000417.853-4.4191-4.34458.438221.648-5.45146.6976-11.093111.255112.5287-7.84059.850416.079317.853QC'd by SIGMAInactive0
Inhibitor14.929466.177610Single point of activity-4.8264.44950.89-59.67766.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0 1-15.344512.41639.71031.67098.92985.04529.81652.21698.6338-9.05192.0403-8.8885-59.3874-15.3445QC'd by CrescentInhibitor14.929443.584610Partial curve; partial efficacy; poor fit-4.8261.24750.7244
Inactive0004-12.3393-5.4707-7.76841.2125-0.9372-2.8638-4.8159-2.7306-8.3906-9.8909-5.1158-7.2832-3.7752-12.3393QC'd by CrescentInactive0
Inactive0004-12.39951.73690.337212.25698.1175-3.8979-0.5168-2.9245-1.5012-11.34040.83976.57380.9346-12.3995QC'd by CrescentInactive0
Inactive0-7.4764.95490.44240.4896-18.399340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.4979-11.8174-3.4832-35.6655-28.5631-0.27183.2831-4.3744-4.3198.29879.438-3.47050.9414-4.4979QC'd by SIGMAInactive0
Inactive000411.53510.193311.9123-7.312714.60326.2774-3.41324.3898-1.954310.42329.88493.05612.716611.5351QC'd by SIGMAInactive0
Inhibitor0.594430.146810Partial curve; partial efficacy; poor fit-6.2263.92950.7596-31.1468-1-2.40 0 0 0 0 0 0 0 0 0 1 1 1 1 19.5925-8.13272.24441.75489.3564-5.7864-0.27772.5376-21.72486.41512.81351.15442.42899.5925QC'd by SIGMAInactive0
Inactive0-5.2763.990.4615-5.34586.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.30194.76232.487611.73962.3257-6.645112.017214.48989.03815.5870.4265-6.2237-6.9549-2.3019QC'd by SIGMAInactive0-4.3764.95490.5619
Inactive00042.05448.146913.882312.5534-5.61650.912412.01381.37735.791415.21471.24863.25714.80342.0544QC'd by SIGMAInactive0
Inhibitor8.395486.565182Complete curve; high efficacy-5.0762.25260.9515-80.06516.5-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-75.405-0.47175.053514.06375.580411.760223.03491.4555-1.71019.2627-17.022-54.0908-79.057-75.405QC'd by SIGMAInactive0-4.3764.95490.4538
Inactive00041.3209-3.56471.30272.7209-12.34330.54250.6416-2.4475-9.1264-0.7083-1.51823.5135-1.75421.3209QC'd by SIGMAInactive0
Inactive00040.14032.2597-2.059213.664116.96353.773113.14130.69514.996-1.62290.30745.6118.65320.1403QC'd by SIGMAInactive0
Inactive0-5.58383.990.6268-0.5-10.788840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.6985-10.3141-12.3897-15.0539-7.0521-6.4389-18.9907-5.2846-10.0691-6.4352-0.26281.1904-1.6416-1.6985QC'd by SIGMAInactive0
Inactive000410.66146.5582-3.2554-3.2146-2.04712.598611.13443.1739-1.526-0.57044.82454.971210.532110.6614QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE506
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/4 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA), followed by addition of 1 only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of 1.25uM NKH477 (0.25 uM as final concentration) in assay medium using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). The plates were incubated at 37 C and 5% CO2 for 3 hrs. Then 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296798 uM-Replicate_1W530-Activity at 0.0003000028 uM-Replicate_1W530-Activity at 0.0006177381 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00519 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.391 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.44 uM-Replicate_1W530-Activity at 92.40 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-7.0159-0.28761.01321.44170.0888-9.1268-1.0522-7.4421-2.13092.3-0.6113-7.015910004-3.4056
Inactive10004-3.011-1.145-2.4844-1.55333.485-0.204-2.4902-1.54362.3767-6.3498-2.685-3.011100040.7393
Inactive10004-0.47-2.8951-3.2523-3.7349-2.26785.50733.05993.31041.24725.2625-0.1696-0.4710004-1.555
Inactive10004-0.09036.7111-0.5976-0.3144-0.47654.1544-6.4709-0.4438-7.8642.2606-1.579-0.0903100040.228
Inconclusive10004-0.2489-6.5215-0.8591-0.5168-7.3815-0.3741.3251-4.3898-1.81870-5.0418-0.24890Single point of activity-4.94454.95490.8866-44.0901-1.7908-30 0 0 0 0 0 0 0 0 0 1 12.9202
Inactive10004-5.6294-14.3173-2.7201-11.2343-4.43723.4425-5.249628.2483-6.79752.1333-6.1463-5.629410-8.24452.33320.5422-2-14.519340 0 0 0 0 0 0 0 0 0 0 1-7.0593
Inactive10004-4.8656-4.3458-5.475-4.89231.908812.6287-0.6734-6.886-6.7235-12.2506-0.9244-4.865610004-0.1056
Inactive100042.05360.3109-7.7771-4.05191.735913.82374.1529-1.641-6.3339-7.8549-1.84152.053610-8.54450.20.35041.5-15.408240 0 0 0 0 0 0 0 0 0 0 01.5023
Inactive100041.8357-3.8712-4.59684.9056-2.4421-0.4821-0.70024.091-5.05424.7764-0.18731.835710-6.84454.95490.3731-1.2664840 0 0 0 0 0 0 0 0 0 0 0-6.472
Inconclusive10-8.44454.95490.4825-0.97971140 0 0 0 0 0 0 0 0 0 0 0-2.985812.2192-7.4831-2.76110.9594.608-1.19161.5553-4.61891.86440.8695-2.98580Complete curve; partial efficacy; poor fit-8.44454.95490.854-2.188620-1.40 0 0 0 0 0 0 0 0 0 0 0-3.7347
Inactive10-7.69454.95490.30740-6.674740 0 0 0 0 0 0 0 0 0 0 16.9665-0.2746-13.4789-0.7541.4976-6.63441.89750.04562.39343.2814-4.07626.966510004-1.252
Inactive10004-0.47391.766-10.94371.36752.373-9.08121.0872-1.62221.10851.03521.2078-0.473910004-1.5827
Inactive10-4.44452.40640.9192-16.0230.540 0 0 0 0 0 0 0 0 0 0 0-13.76922.63221.58520.43591.6531-1.4042-0.73890.9511-0.33230.0369-10.5155-13.769210-4.19454.95490.57139-3.14940 0 0 0 0 0 0 0 0 0 0 07.2634
Inactive100048.62161.66121.39551.5105-8.28851.1474-1.52842.0426-0.73990.4137-1.85788.621610004-2.0298
Inactive10004-4.4756-0.29490.23863.43141.14790.7678-0.0067-0.6507-5.9741-0.2067-0.9416-4.475610004-3.061
Inactive100045.8601-2.39410.0423-2.0754.7846.2997-0.85951.393-3.01113.55965.32115.860110004-9.2067
Inconclusive10-4.24454.95490.427210.5-2.309340 0 0 0 0 0 0 0 0 0 0 09.5331-2.85560-1.2063-0.52341.9291-1.3959-2.6682-0.0439-13.5911-0.2019.533110-4.19454.95490.4089-3.448340 0 0 0 0 0 0 0 0 0 0 07.6869
Inactive10-4.28664.95490.72825.5-1.172640 0 0 0 0 0 0 0 0 0 0 023.3828-8.06053.02756.3622-3.8991.2563-5.1797-5.777-0.78790.19013.771823.382810-4.18664.95490.6532-22.1907-340 0 0 0 0 0 0 0 0 0 0 0-18.4923
Inconclusive100045.4646-3.9154-3.2006-6.41313.52925.1932-1.12710.5761-20.3247-0.5782-7.18015.464610004-5.264
Activator45.240774.820710-7.89454.95490.36863-7.172940 0 0 0 0 0 0 0 0 0 0 1-4.09-4.1888-10.14418.5838-1.725112.80163.66663.2286-2.06960.7385-1.1706-4.090Partial curve; high efficacy-4.34453.06540.983172.728-2.09272.10 0 0 0 0 0 0 0 0 0 0 064.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE623
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/5 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA). After the plates were incubated at 37 C/5% CO2 for 3 hrs, 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.9548-0.4195-0.08090.01770.7848-1.9753-7.8495-0.2201-5.8525-0.1843-6.667-6.1435-0.8948-0.9548100040.4943
Inconclusive33.491535.467210Single point of activity-4.47514.95490.843234-1.467230 0 0 0 0 0 0 0 0 0 0 0 0 0 031.5847-0.2053.1711-0.15032.02621.8413-4.6774-6.6393-0.2496-0.3165-2.4959-5.1038-6.43831.5847100040.7055
Fluorescent21.1317233.52310Partial curve; high efficacy-4.67511.66040.9916233.382-0.14082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0187.9080.2599-1.6287-1.3781-0.2984-4.561-5.7662-0.1876-0.89793.775318.200944.8649106.298187.90810004-7.3866
Inactive10-9.12514.95490.3604-3.3986940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.97486.1565-4.2866-4.2034-1.1608-2.7993-8.2488-3.77590.147-6.6878-0.72651.7247-4.6409-3.9748100040.7006
Inactive10004-2.523-0.126-0.55750.26870.577-0.4465-1.82971.4459-0.8687-0.2229-1.2617-1.1583-2.804-2.523100040.1481
Inactive10004-3.3158-2.46060.8744-2.4805-1.96530.2783-2.1155-3.1759-0.73280.0273-2.7411-1.1742-2.5861-3.3158100040.3542
Inactive10004-6.3298-3.0655-0.5983-3.9559-3.2297-0.1472-0.9072-0.8472-0.4548-2.3342-4.8197-0.9701-5.2874-6.3298100040.0515
Inactive10004-1.6718-2.7534-3.0434-3.2368-0.5266-0.94970.8324-0.4991-0.1271-2.3961-5.9765-2.88891.3265-1.671810004-0.8308
Inactive100040.2704-0.01130.2093-0.13591.8534-1.9442-1.318-1.36660.26060.3476-0.5964-4.328-0.650.2704100040.2962
Inactive100046.1074-1.09610.1205-0.9377-0.83138.31174.16744.893111.21568.51340.08540.32950.12876.107410004-1.6275
Inconclusive66.265742.352310Partial curve; partial efficacy; poor fit-4.17872.18760.744138.0307-4.32152.40 0 0 0 0 0 0 0 0 0 0 0 0 0 029.2246-1.7761-13.0089-0.6771-0.1398-0.17050.3188-8.468-7.9781-16.97650.4529-0.721710.880929.224610004-3.7076
Fluorescent28.616390.842810Partial curve; high efficacy-4.54341.10.981890.3256-0.51722.10 0 0 0 0 0 0 0 0 0 0 0 0 0 071.8878-4.4616-0.0053-3.23970.62975.4330.79530.3464.285511.413917.470133.335455.296271.8878100044.8243
Inconclusive34.66854.985810Partial curve; partial efficacy-4.46011.10.947255.96930.98352.20 0 0 0 0 0 0 0 0 0 0 0 0 0 046.8430.3409-1.0852-0.7636-0.33174.23040.81593.05980.71718.24410.756619.145128.547346.84310004-3.0992
Inactive100040.2088-0.50992.4533-1.9209-0.41840.4617-1.05255.94946.28828.7636-0.5450.9216-2.79590.208810004-1.4861
Inconclusive49.734642.262210Partial curve; partial efficacy-4.303310.807245.23142.96912.20 0 0 0 0 0 0 0 0 0 0 0 0 0 039.7015-0.61882.84480.88810.00942.76685.875211.958.22448.9497.06849.448122.15539.701510004-4.3489
Inconclusive30.869639.274510Partial curve; partial efficacy-4.51052.63840.979938.9369-0.33752.20 0 0 0 0 0 0 0 0 0 0 0 0 0 038.3807-0.22181.8163-0.7660.9433-1.62850.7273-1.86440.5114-1.39731.36159.830428.899138.380710004-3.1002
Inconclusive62.725631.99510Partial curve; partial efficacy; poor fit-4.20263.24750.808229-2.9952.40 0 0 0 0 0 0 0 0 0 0 0 0 0 023.8094-4.1625-1.3901-1.5226-0.3825-8.32920.3951-6.4986-0.4749-5.7267-0.3547-1.45245.496723.809410004-4.0375
Inactive10-4.39591.69240.5803-7.38343.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.8195-0.15651.02455.34581.68774.78684.9925.87394.32077.04250.0148-0.2167-0.2419-7.8195100040.8078
Inactive10-5.99513.92950.3374-3.0208240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7098-0.61051.9344.08050.45173.65393.7594-0.97033.256-6.2855-0.62940.2278-0.9853-6.7098100040.5022
Inactive10-4.06410.80.6276240.821840 0 0 0 0 0 0 0 0 0 0 0 0 0 017.14390.83390.9785-2.37282.60513.2312-0.1354-1.67722.75114.08237.28953.67335.072317.143910004-1.6432
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS574
Protocol: Please refer to other AIDs 1963577 and 1963579 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with human microsomes agonist mode assay (AID 1963577), cell viability counter screen (AID 1963579), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist1.217408778.37631949inconclusive agonistactive agonist0.64630334178.39811596inactive0inactiveLightBiologicals
active agonistactive agonist0.43195290759.28553099active agonist0.91292773444.30993466active agonist0.55433172482.63203296inactive0inactiveLightBiologicals
active agonistactive agonist1.92946276175.72635936inconclusive agonistactive agonist1.39241833793.4523553inactive0inactiveLightBiologicals
active agonistactive agonist0.90676599358.50333518active agonist0.30731181552.96240355active agonist0.50725702284.98953543inactive0inactiveLightBiologicals
active agonistactive agonist0.46322605451.84457808active agonist0.58316704959.08400159active agonist0.56121117687.34471148inactive0inconclusiveCrescent
active agonistactive agonist3.97431503881.35179825inconclusive antagonist6.298864848-55.06041593inconclusive agonistactive antagonist8.897383087-112.1712623inactiveMicrosource
active agonistactive agonist2.57297994471.82694939inconclusive agonistactive agonist1.5623190775.01686917inactive0inactiveLightBiologicals
active agonistactive agonist0.96702210456.88216128inconclusive agonistactive agonist0.813647772.2886186inactive0inactiveLightBiologicals
active agonistactive agonist2.16489282570.10936057inconclusive agonist0.16234405951.55911786active agonist0.78301437374.08029793inactive0inactiveSIGMA
active agonistactive agonist1.18648510457.37963601active agonist2.1099020365.82498706active agonist1.30595723699.20329811inactive0inactiveSequoia
active agonistactive agonist0.94245861853.83876935inactive0active agonist1.12011416783.34522444inactive0inactivePharmaron
active agonistactive agonist1.13670862258.22057975active agonist0.38813471546.97356994active agonist0.69021197284.87369086inactive0inactiveSigmaAldrich
active agonistactive agonist1.37140703260.17931711inconclusive agonist8.16895252360.48218607active agonist3.94003160970.47314257inactive0inactiveFisher
active agonistactive agonist1.30131434158.4681202inconclusive agonistactive agonist0.88657513973.04049532inactive0inconclusiveSIGMA
active agonistactive agonist0.43195290746.46415354active agonist1.02432176549.29568673active agonist0.57601845974.36852288inactive0Sigma Chemical Company
active agonistactive agonist2.1099020362.60069161inconclusive agonistactive agonist1.20947145569.12030947inactive0inactiveSIGMA
active agonistactive agonist3.97431503876.85083297inconclusive agonist0.0792980148.75406392active agonist1.844713627108.3175397inactive0inactiveChemos
active agonistactive agonist4.07789839875.41728704inconclusive agonistactive agonist5.54331724488.76279206inactive0inactiveLightBiologicals
active agonistactive agonist3.23918983670.70756618inconclusive agonistactive agonist4.40321340175.21515029inactive0inactiveLightBiologicals
active agonistactive agonist3.84978433576.47198713inconclusive agonistactive agonist2.29317078985.70280133inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53654
Protocol: Please refer to other AIDs 1963582 and 1963581 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 agonist mode assay (AID 1963582), cell viability counter screen (AID 1963581), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist0.047234823152.29472inactive0active agonist0.037519953136.8633354inactive0GVK
active agonistactive agonist0.844238379220.2162354inconclusive antagonistactive agonist0.512623398104.6191287inactive0inactiveToronto Research
active agonistactive agonist0.012094715104.4361664inconclusive agonistactive agonist0.011201142144.4467864active antagonist0.397431504-70.21237763inactiveSelleck
active agonistactive agonist1.209471455180.1226065inactive0active agonist0.606171653113.571674inconclusive agonistinactiveSequoia
active agonistactive agonist2.778239835211.6412216inconclusive agonist48.4659132967.35167123active agonist5.13376992205.3954222inactive0inconclusiveSigmaAldrich
active agonistactive agonist13.57817889353.547094active antagonist13.06696898-36.85413308active agonist12.57500577253.5649028active agonist2.9828481548.90133363inactiveMicrosource
active agonistactive agonist0.13570492993.31141224inconclusive antagonist0.188045216-22.20736842active agonist0.14101401985.04743995inactive0inactiveSequoia
active agonistactive agonist0.16450339394.32096258inconclusive antagonistactive agonist0.36827722384.98769167inconclusive agonistinactivePrestwick
active agonistactive agonist9.486435714254.9932329active antagonist5.985536287-48.49725447active agonist8.136476998139.346131inactive0inactivePharma
active agonistactive agonist8.399671273237.8402483active antagonist1.410140188-48.09733887active agonist7.071445409180.865123inconclusiveinactiveMicrosource
active agonistactive agonist0.09129277384.95609526inactive0active agonist0.05437964977.70981018inactive0inconclusiveAcros
active agonistactive agonist4.38376925182.3000923active antagonist5.111099704-51.21597367active agonist3.48215169122.7336497inactive0inactiveSigmaAldrich
active agonistactive agonist1.993004104142.3810228inconclusive antagonistactive agonist5.202054047130.3026231inactive0inconclusiveSIGMA
active agonistactive agonist0.500619997103.8418341inactive0active agonist0.856725169155.0303204inconclusive antagonist0.562341325-43.25974821inactiveVitas
active agonistactive agonist0.12094714681.97009147inconclusive agonistactive agonist0.103735871123.2085258active antagonist0.70674426-72.37265734inactiveSequoia
active agonistactive agonist2.815193123137.0716961active antagonist3.159593015-33.41462647active agonist2.15199632892.29790016inactive0inactiveMicrosource
active agonistactive agonist0.61789561391.22925261inactive0active agonist1.809596631101.0029829inactive0inconclusiveSIGMA
active agonistactive agonist0.55433172483.79635801inactive0active agonist1.39241833788.81361331inactive0inactiveSIGMA
active agonistactive agonist0.43195290778.01689897inconclusive agonistactive agonist0.37766180899.59298459active agonist0.51337699277.40150829inactiveRoche
active agonistactive agonist2.605727258108.4007283inconclusive agonistactive agonist1.916883076121.5082983active antagonist2.507623262-38.90785093inactiveMicrosource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A603
Protocol: Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049636 uM-Replicate_1Activity at 0.0000112894 uM-Replicate_1Activity at 0.0000451294 uM-Replicate_1Activity at 0.0001083383 uM-Replicate_1Activity at 0.0002490219 uM-Replicate_1Activity at 0.0005090755 uM-Replicate_1Activity at 0.00139 uM-Replicate_1Activity at 0.00429 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.128 uM-Replicate_1Activity at 0.292 uM-Replicate_1Activity at 0.874 uM-Replicate_1Activity at 2.651 uM-Replicate_1Activity at 7.023 uM-Replicate_1Activity at 15.88 uM-Replicate_1Activity at 35.56 uM-Replicate_1Activity at 76.84 uM-Replicate_1Activity at 198.7 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.67131.10.547980.819540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.7235-1.7246-0.79674.02471.9622-1.14673.4822-1.5146-1.8176.06554.31945.62146.74618.7235QC'd by ACCInactive0
Inactive00040.71362.84913.15472.62081.73272.79433.62882.21110.9461-1.0072-0.4977-1.0290.49570.7136QC'd by ACCInactive0-6.67134.95490.4722
Activator23.9145533.488243Partial curve; high efficacy-4.62131.98870.987537.0293.54082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0406.84010.49816.65853.85970.56377.39464.5987-3.71610.781112.19813.264681.5331158.4589406.8401QC'd by ACCActivator18.9959357.953744Partial curve; high efficacy-4.72131.34430.9586
Inactive0004-3.33330.3686-2.1838-0.97840.28920.0634-2.0419-0.18710.061-3.3304-2.6853-2.00990.2108-3.3333QC'd by ACCInactive0
Inactive00043.36520.94171.36941.3511-0.11411.40170.29941.14555.12170.75433.87762.18824.52673.3652QC'd by RTIInactive0
Inactive0-4.96951.88510.9211-14.6405140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.45042.42870.3370.34840.7070.60323.1373-1.09171.7571-3.2954-1.1568-10.861-12.9725-13.4504QC'd by RTIInactive0-4.41952.18760.6553
Activator0.075282.249290Complete curve; high efficacy-7.12350.80.98879.7492-2.51.10 0 0 0 0 0 0 0 0 0 0 0 0 0 080.83461.78786.13089.925819.761739.591652.77160.918266.105569.033480.327881.334383.594680.8346QC'd by RTIActivator0.474788.523888Complete curve; high efficacy-6.32350.90.9909
Activator0.265393.198289Complete curve; high efficacy-6.57630.80.995589.1185-4.07971.10 0 0 0 0 0 0 0 0 0 0 0 0 0 090.5676-0.8998-0.035-0.36238.222717.297432.011448.365862.041171.971786.9385.895983.583490.5676QC'd by RTIActivator0.026577.546693Complete curve; high efficacy-7.57630.90.987
Inactive0-4.13091.24750.8779-16.497-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.58080.1628-0.5762-1.1136-0.2048-0.368-0.8819-0.8283-2.0195-1.2058-1.9466-7.6162-7.0211-14.5808QC'd by RTIInactive0
Inactive0004-6.6585-1.8147-3.036-2.7414-2.9382-3.1098-0.24922.1427-2.6629-0.1939-2.7488-1.4566-8.5268-6.6585QC'd by RTIInactive0
Inactive0004-3.4757-0.43290.3326-0.84020.0544-2.7307-0.3172-1.3413-2.0597-1.0047-1.1604-1.2522-8.0139-3.4757QC'd by RTIInactive0-4.0751.10.6917
Activator57.586431.97110Partial curve; partial efficacy; poor fit-4.23974.95490.909830-1.9712.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7904-1.4056-0.3633-0.0089-3.0195-0.599-0.5758-0.7948-0.4323-4.1986-5.0136-5.39250.354724.7904QC'd by RTIInactive0
Activator62.154948.383510Single point of activity-4.20654.95490.969648.1294-0.254130 0 0 0 0 0 0 0 0 0 0 0 0 0 039.8328-0.49521.4760.66241.9344-0.3395-0.7123-1.4037-1.73662.2992-2.7117-1.43311.585639.8328QC'd by RTIActivator55.395689.54741Partial curve; high efficacy-4.25652.58840.9752
Inactive0004-1.5545-1.6566-2.6838-1.6155-1.2771-2.8033-0.7992-2.2086-2.1165-1.43662.10792.0395-0.1964-1.5545QC'd by RTIInactive0
Inactive0-6.44991.96730.9648-15.489-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8883-0.1006-0.005-1.1316-1.8411-1.5843-1.4803-6.9758-12.1972-15.4653-17.0742-15.8774-16.437-11.8883QC'd by RTIInactive0-7.24990.90.9292
Inactive0-6.7574.95490.7181-12.0035140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.7465-0.46011.86560.11251.6950.44190.0198-17.5030.0822-10.7704-15.9134-13.7319-15.7608-11.7465QC'd by RTIInactive0-6.6074.95490.7096
Inactive0-5.39891.62660.717541440 0 0 0 0 0 0 0 0 0 0 0 0 0 02.18889.749913.244215.360917.054711.082914.114214.655317.559610.40557.12343.60218.61112.1888QC'd by RTIInactive0
Activator0.00149.315210Complete curve; high efficacy; poor fit-8.99190.40.646890.475241.161.30 0 0 0 0 0 0 0 0 0 0 0 0 0 087.673963.476275.320673.937776.90881.009883.341778.7232103.994589.298187.72991.364785.620587.6739QC'd by RTIActivator5.0E-480.912699Complete curve; high efficacy-9.29190.60.7869
Activator1.440861.767884Complete curve; high efficacy-5.84141.47870.990864.30992.54211.10 0 0 0 0 0 0 0 0 0 0 0 0 0 062.09883.60835.35485.57370.9311-2.04832.24227.913418.225242.68557.609265.591966.455462.0988QC'd by RTIActivator1.616683.116985Complete curve; high efficacy-5.79140.80.9937
Inactive0-5.36041.96730.3672-14.2663-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.6859-5.5953-3.7533-2.9145-1.4897-2.1001-2.8826.1673-6.0115-4.3461-9.4884-15.1664-14.9205-12.6859QC'd by RTIInactive0-5.56044.0950.9954
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A875
Protocol: Tox21 Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of 4-Iodo-2,5-dimethoxy-alpha-methylbenzeneethanamine hydrochloride (DOI) at 4nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039737 uM-Replicate_1Activity at 0.0000090357 uM-Replicate_1Activity at 0.0000361304 uM-Replicate_1Activity at 0.0000867348 uM-Replicate_1Activity at 0.0001993648 uM-Replicate_1Activity at 0.0004075545 uM-Replicate_1Activity at 0.00112 uM-Replicate_1Activity at 0.00343 uM-Replicate_1Activity at 0.00899 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.046 uM-Replicate_1Activity at 0.103 uM-Replicate_1Activity at 0.233 uM-Replicate_1Activity at 0.700 uM-Replicate_1Activity at 2.122 uM-Replicate_1Activity at 5.622 uM-Replicate_1Activity at 12.72 uM-Replicate_1Activity at 28.47 uM-Replicate_1Activity at 61.52 uM-Replicate_1Activity at 159.1 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-7.2061-3.526-9.9489-2.97267.0388-5.0617-5.7675-3.6219-0.0251-2.7206-1.11990.8657-10.4359-7.2061QC'd by SIGMAInactive0
Inactive00046.13445.64138.53264.04038.44095.441410.92884.31674.82284.80260.47619.71629.14296.1344QC'd by WaterstoneInactive0-8.6263.06540.5917
Inactive00042.3205-1.4158-3.9188-1.2064-7.0528-5.2123-2.2684-6.0073-2.0124-4.3471-2.4408-5.7061-1.99452.3205QC'd by SIGMAInactive0
Inactive00040.29564.40161.67061.4091-1.97283.5850.63440.38270.4984-2.7333.67393.46242.37810.2956QC'd by LightBiologicalsInactive0
Inactive0004-6.96170.1347-10.9722-11.3789-0.9886-3.2185-2.6238-5.3048-2.66760.8444-8.24951.4346-0.1703-6.9617QC'd by LightBiologicalsInactive0
Inactive0-4.9264.95490.47717-3.149540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.9844-4.3701-1.7004-8.87464.1299-5.48120.94572.1614-3.6786-2.2479-8.06382.37734.41318.9844QC'd by SIGMAInactive0
Inactive00042.7598-1.388-10.7501-2.243-7.1709-7.7234-0.86450.53450.11642.5902-8.76125.54313.50742.7598QC'd by LightBiologicalsInactive0
Inactive0-5.65821.46410.408-4.6092240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.78232.28384.9364.2099-4.16470.83986.4512-0.0288-0.01385.2677-3.4901-4.5008-2.3051-5.0910.7823QC'd by SIGMAInactive0
Inactive00043.79320.7208-1.6962-3.28710.9942-4.8215.321-4.7996-0.71224.43679.43390.65277.89283.7932QC'd by SIGMAInactive0
Inactive00041.00171.7707-1.3919-0.9574.20364.12342.9095-0.1743.60228.54267.03274.49020.66171.0017QC'd by TCIInhibitor0.167523.871710Single point of activity-6.7764.95490.6462
Inactive00041.3141-0.92173.5166-2.30331.6783.27250.5745-9.0E-41.5868-0.40153.79654.99052.65621.3141QC'd by SIGMAInactive0
Inactive0-5.62610.41615-3.772340 0 0 0 0 0 0 0 0 0 0 0 0 0 06.036-2.1149-5.697-13.97690.09992.219-1.9463-2.9706-3.34883.16550.39146.03741.34256.036QC'd by SIGMAInactive0
Inhibitor9.419843.686410Single point of activity-5.0264.95490.8559-47.6864-4-30 0 0 0 0 0 0 0 0 0 0 0 0 1 1-4.2356-9.8138-9.423-4.05922.411-1.0589-7.4879-2.3574-4.7276-3.6806-4.4603-38.39886.5491-4.2356QC'd by LightBiologicalsInactive0-7.0260.20.4384
Inactive0004-0.06471.12492.86741.33545.11772.14-1.44271.18032.9089-1.5124-0.02495.72685.9847-0.0647QC'd by LightBiologicalsInhibitor47.210925.535310Partial curve; partial efficacy; poor fit-4.3264.95490.7127
Inactive0-6.42610.55530.5-8.527640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.5555-7.8118-8.811-10.011-6.4119-10.1734-6.8978-2.0059-5.3563.4401-1.34733.18-0.9271-0.5555QC'd by LightBiologicalsInactive0
Inactive00041.97624.76444.171228.06640.678-1.83649.05051.55284.31155.40685.86384.23756.04841.9762QC'd by SIGMAInactive0
Inactive0004-2.38713.6232-0.273903.5491.08915.48920.99120.71813.3244-2.86665.65283.6147-2.3871QC'd by LightBiologicalsInactive0
Inactive000413.15252.6229-1.041215.1602-2.820813.804212.821710.52165.190911.06815.40983.05368.005213.1525QC'd by SIGMAInactive0
Inactive0-5.2761.10.6487-16.0176-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.848-6.15315.9102-2.0982-1.5437-3.338-2.63271.5609-0.7495-10.8518-7.7926-9.3193-14.5467-15.848QC'd by LightBiologicalsInactive0-4.6261.3310.6582
Inactive00040.0466-2.72680.2154-0.12984.7191-1.4011-1.10474.8769-0.64661.98962.8818-2.35198.50421.5602QC'd by AcrosInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs0.6314-10.976Green
10NEROLMicrosource12.58934-28.228Green
3Phenol redLabotest0.7079419.263Green
4Aminoquinuride dihydrochlorideLabotest0.7079418Green
3Pyridoxamine DihydrochlorideBosche15.84894-11.767Green
7CarzenideLabotest0.631411.002Green
9PridinolSpecs102.236.664Green
3L-LeucineBosche0.8913414.333Green
6FenticlorVitas3.16234-28.657Green
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.8107-3-98.319Green
8BenzbromaroneLabotest1.7783416.5Green
8Phosphonoacetic acidSIGMA14-15.333Green
17DomperidoneMicrosource25.11892.3125.472Green
4PifexoleBionet0.6314-9.778Green
15WY-14643SIGMA3.9811419.845Green
14OXAPROZINMicrosource39.8107418.153Green
6Topotecan hydrochloridePrestwick31.622851429.488Green
12AZELAIC ACIDMicrosource10417.221Green
13AmoxapineEnzo8.91252.394.86Green
14R-(+)-AtenololVitas104-16.344Green
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_ratio
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs40ratio
10NEROLMicrosource0.6314-18.609ratio
3Phenol redLabotest8.9125411.059ratio
4Aminoquinuride dihydrochlorideLabotest19.95262.395.842ratio
3Pyridoxamine DihydrochlorideBosche44.66844-13.116ratio
7CarzenideLabotest40ratio
9PridinolSpecs28.18382.3104.274ratio
3L-LeucineBosche0.79434-27.61ratio
6FenticlorVitas15.84892.459.259ratio
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.370.654ratio
8BenzbromaroneLabotest7.9433419.539ratio
8Phosphonoacetic acidSIGMA7.943349.28ratio
17DomperidoneMicrosource25.1189387.928ratio
4PifexoleBionet3.54814-20.543ratio
15WY-14643SIGMA3.9811-3-98.934ratio
14OXAPROZINMicrosource39.8107416.681ratio
6Topotecan hydrochloridePrestwick7.94332.183.464ratio
12AZELAIC ACIDMicrosource40ratio
13AmoxapineEnzo102.1101.678ratio
14R-(+)-AtenololVitas40ratio
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_blue
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs104-14.43blue
10NEROLMicrosource40blue
3Phenol redLabotest39.81074-13.607blue
4Aminoquinuride dihydrochlorideLabotest22.38722.395.429blue
3Pyridoxamine DihydrochlorideBosche40blue
7CarzenideLabotest40blue
9PridinolSpecs31.6228398.957blue
3L-LeucineBosche0.3981-1.4-35.007blue
6FenticlorVitas102.251.546blue
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.390.071blue
8BenzbromaroneLabotest11.2202418.74blue
8Phosphonoacetic acidSIGMA7.9433411.21blue
17DomperidoneMicrosource39.8107390.852blue
4PifexoleBionet3.54814-15.204blue
15WY-14643SIGMA3.9811-3-135.758blue
14OXAPROZINMicrosource44.668448.931blue
6Topotecan hydrochloridePrestwick0.6314-18.88blue
12AZELAIC ACIDMicrosource1.1224-15.036blue
13AmoxapineEnzo14.12542.190.875blue
14R-(+)-AtenololVitas40blue
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40657
Protocol: Tox21 Assay Protocol Summary:

300 DT40 mutant cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00617 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.535 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.01123.097-15.61374.831817.24522.68492.87025.838-1.15092.4566-15.0143-1.83128.71463.75322.72683.0112QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.1785-10.892-15.6985-0.69210.4103-15.63332.8403-15.8637-6.5703-13.149-26.3626.1142-10.7498-15.5641-24.2196-2.1785QC'd by Sigma DiscoveryCPRCytotoxic68.589691.523642Partial curve; high efficacy-4.16373.24750.8975-95.1787
Inactive04-10.4836-24.2062-15.4625-22.1853-17.0029-23.7071-26.4511-5.4538-39.9631-45.6107-35.4677-32.0907-29.217-24.9641-27.9971-10.4836QC'd by Sigma DiscoveryCPRCytotoxic61.130629.401520Partial curve; partial efficacy; poor fit-4.21371.88510.8107-31.9015
Inactive04-4.59729.3751-8.1926-3.89550.6461-8.566213.4774-0.62345.5343-3.2761-6.0086-5.24710.8659-3.3104-0.8139-4.5972QC'd by Sigma DiscoveryCPRInactive04.95490.6911-27.7726
Inactive01.3310.4841-18.2848-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4341-15.6941-0.6359-0.217-0.01279.76010.47981.0579-3.8901-4.4074-0.2904-14.3809-1.6368-26.0707-15.5655-15.4341QC'd by Sigma DiscoveryCPRCytotoxic68.589696.936120Single point of activity-4.16374.95490.9116-96.8607
Cytotoxic68.589648.251420Single point of activity-4.16374.50450.669-42.75145.5-30 0 0 0 0 0 0 0 0 0 0 1 0 0 0-32.76366.68717.171221.5873-4.0029-2.3442-2.24135.53994.60832.4453-0.50548.148-24.60336.40680.6319-32.7636QC'd by Sigma DiscoveryCPRCytotoxic68.589648.174420Single point of activity-4.16374.95490.9289-45.8879
Inactive00.30.7121-33.8051140 0 0 0 0 0 0 0 0 0 0 1 0 0 0-24.382310.43845.12726.81657.22591.8658-8.6709-16.2528-6.24420.3161-1.6373-7.5312-91.6148-26.0875-17.5667-24.3823QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic30.637967.376140Partial curve; high efficacy-4.51370.90.775-65.03912.337-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-60.304212.047412.9559-2.1973-12.63497.3969-3.88253.660712.6478-6.4422-9.9361-12.776-9.7544-22.4301-24.4994-60.3042QC'd by Sigma DiscoveryCPRCytotoxic61.130636.052220Partial curve; partial efficacy; poor fit-4.21374.95490.8632-33.5522
Cytotoxic61.1306111.553142Partial curve; high efficacy-4.21373.990.9734-113.6335-2.0804-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.65118.3666-2.0713-3.7808-2.35050.04213.1312-0.1348-6.3457-2.025-7.1259-0.3043-6.8314-6.1688-21.3977-95.6511QC'd by Sigma DiscoveryCPRInactive0
Inactive04-12.7888-1.057-2.0848-0.7554-6.8445-0.3896-2.5669-0.3877-3.83473.37538.0661-13.2548-2.828516.492-3.484-12.7888QC'd by Sigma DiscoveryCPRInactive01.69240.56086
Cytotoxic68.5896120.709842Partial curve; high efficacy-4.16374.95490.9332-122.3541-1.6443-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.4749-0.52770.547410.1427-1.25254.012-10.9614-1.4029-7.26650.8155-18.27654.3116-4.27371.9509-11.5455-99.4749QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6075-28.619-440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.4325-14.8758-0.7818-11.7063-0.11123.04971.97010.8638-15.4171-14.52550.3742.40541.2793-11.955-27.2415-28.4325QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6053-25.3863340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.9053-3.0798-0.16165.81434.36872.6264-2.68023.478213.64463.777-0.6631-2.940811.09824.56250.5366-19.9053QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.2887-9.33222.806-1.96982.835-19.1802-2.244-2.376111.6639-4.3953-0.88963.7875-1.1556-17.5934-15.146-2.2887QC'd by Sigma DiscoveryCPRInactive04.95490.74112
Cytotoxic68.5896121.561120Single point of activity-4.16374.95490.9451-122.6489-1.0878-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-100.2033-11.91628.5759-4.0103-8.04752.09744.9269-4.8191-8.6034.1695-6.8431-3.09872.96934.092-4.7679-100.2033QC'd by Sigma DiscoveryCPRInactive0
Inactive00.60.4241-16.80689.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.33918.7614-0.1122-2.521314.32534.912525.50638.89340.001311.5099-6.67791.0565-0.13852.7506-11.651-12.339QC'd by SIGMACytotoxic20Single point of activity
Inactive00.50.4566-0.24781040 0 0 0 0 0 0 0 0 0 0 0 0 0 02.05936.68268.657811.23617.42261.45222.14479.27011.79030.5244-3.08084.58743.84151.4091-6.45652.0593QC'd by Sigma DiscoveryCPRInactive04.0450.6801-25.4596
Inactive04.95490.4416-12.802440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.75170.2533-2.853315.69095.351413.8457-0.7219-3.2206-0.93875.440912.5372-1.28440.86326.1393-10.3064-12.7517QC'd by Sigma DiscoveryCPRInactive0
Inactive01.64360.3324-17.01442.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.845410.67053.9496.78270.3479-1.2699-8.220512.82270.96571.1019-3.13092.35830.7293-0.3373-3.38-10.8454QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic0.136975.828189Complete curve; high efficacy-6.86371.46410.9678-76.2529-0.4248-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.61070.6376-4.1922-1.0881-0.5964-10.0644-14.6504-42.7191-72.2882-55.2459-69.9677-74.6041-73.5035-77.875-80.4615-83.6107QC'd by Sigma DiscoveryCPRCytotoxic0.216966.648687Complete curve; high efficacy-6.66374.95490.9621-68.4642
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EM141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 70% are deemed active, and the activity outcome is set to 2.

Note that this scoring scheme only applies to the ratio of blue/green fluorescence intensities because it is this ratio that represents the activity of Bla inside cells. Separate uploads of blue and green data exist in this assay group but information on activity should not be derived from these.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample nbumberSample NameSupplierAc50Curve ClassEfficacyChannelChannel typeConc0Conc1Conc2Conc3Conc4Conc5Conc6Conc7Conc8Conc9Conc10Data0Data1Data2Data3Data4Data5Data6Data7Data8Data9Data10
10NEROLMicrosource12.589254124-28.228greenused to calculate ratio0.462.311.557.59.1270994759.61618564-3.7770449-15.60632145
3Phenol redLabotest0.707945784419.263greenused to calculate ratio0.462.311.557.5-9.385966028.828293685.796660949.22493965
4Aminoquinuride dihydrochlorideLabotest0.707945784418greenused to calculate ratio0.462.311.557.53.4615238822.8010761516.029539420.72614656
3Pyridoxamine DihydrochlorideBosche15.848931924-11.767greenused to calculate ratio0.462.311.557.53.2822761710.932088973.29047462-4.38930637
7CarzenideLabotest0.630957345411.002greenused to calculate ratio0.462.311.557.5-14.81373825-4.81206699-6.89129672-12.75493009
9PridinolSpecs102.236.664greenused to calculate ratio0.462.311.557.51.799217293.4608488822.2949210337.40401694
4ProcodazoleVitas0.6309573454-21.162greenused to calculate ratio0.462.311.557.511.00151234-9.702208834.56604819-14.71822198
3L-LeucineBosche0.891250938414.333greenused to calculate ratio0.231.155.7528.7-10.277274430.797956196.033257572.21607206
6FenticlorVitas3.162277664-28.657greenused to calculate ratio0.462.311.557.51.97467363-4.86579376-26.3812188411.38643713
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.810717065-98.319greenused to calculate ratio0.462.311.557.58.229873113.4401888532.34629485-69.99258758
9Cyclobenzaprine hydrochlorideMicrosource15.848931922.1107.682greenused to calculate ratio0.462.311.557.5-15.91101847-4.2171917225.3285511382.99755874
8Phosphonoacetic acidSIGMA14-15.333greenused to calculate ratio0.462.311.557.57.40981797-5.05293193-1.67180124-11.11044314
17DomperidoneMicrosource25.118864322.1125.472greenused to calculate ratio0.462.311.557.5-10.68996778-0.4700079216.1055883196.36730961
4PifexoleBionet0.6309573454-9.778greenused to calculate ratio0.462.311.557.5-0.02107281-10.25290078-6.57120927-2.6114683
15WY-14643SIGMA3.981071706419.845greenused to calculate ratio0.462.311.557.5-1.53727228-0.6332131222.4891074413.55929131
14OXAPROZINMicrosource39.81071706418.153greenused to calculate ratio0.462.311.557.55.23106550.41003145-0.5438345216.85882561
6Topotecan hydrochloridePrestwick31.62277662.11429.488greenused to calculate ratio0.462.311.557.533.64911259138.5512222284.01020061141.705944
12AZELAIC ACIDMicrosource10417.221greenused to calculate ratio0.462.311.557.5-7.26743084-1.90015675-1.269343046.54169513
13AmoxapineEnzo8.9125093812.194.86greenused to calculate ratio0.462.311.557.5-4.771443380.0424582366.6559176193.16864781
14R-(+)-AtenololVitas104-16.344greenused to calculate ratio0.462.311.557.5-9.75671331-3.63184443-17.25199222-4.91153437